

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2005267396 B2**

- (54) Title
Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
- (51) International Patent Classification(s)
A61K 9/14 (2006.01)
- (21) Application No: **2005267396** (22) Date of Filing: **2005.06.23**
- (87) WIPO No: **WO06/012146**
- (30) Priority Data
- | (31) Number | (32) Date | (33) Country |
|-------------------|-------------------|--------------|
| 10/874,552 | 2004.06.24 | US |
| 11/019,243 | 2004.12.23 | US |
- (43) Publication Date: **2006.02.02**
- (44) Accepted Journal Date: **2009.09.17**
- (71) Applicant(s)
IDEXX Laboratories, Inc.
- (72) Inventor(s)
Murthy, Yerramilli, V. S. N.
- (74) Agent / Attorney
Spruson & Ferguson, Level 35 St Martins Tower 31 Market Street, Sydney, NSW, 2000
- (56) Related Art
US 6 669 958
JP 60087215
Handbook of Pharmaceutical Controlled Release Technology (ed Wise) 2000

(19) World Intellectual Property Organization
International Bureau



PCT



(43) International Publication Date
2 February 2006 (02.02.2006)

(10) International Publication Number
WO 2006/012146 A2

(51) International Patent Classification:
A61K 31/704 (2006.01) *A61K 9/14* (2006.01)
A61K 31/165 (2006.01)

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2005/022073

(22) International Filing Date: 23 June 2005 (23.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/874,552 24 June 2004 (24.06.2004) US
11/019,243 23 December 2004 (23.12.2004) US

(71) Applicant (for all designated States except US): **IDEXX LABORATORIES, INC.** [US/US]; One Idexx Drive, Westbrook, MA 04092 (US).

(72) Inventor: **MURTHY, Yerramilli, V., S., N.**; 2212 Oak Stream Lane, Apex, NC 27523 (US).

(74) Agents: **DIETZE, Paul, E.** et al.; Kenyon & kenyon, 1500 K Street N.W., Suite 700, Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF TREATING OR PREVENTING CONDITIONS USING SAME

(57) Abstract: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained- release of a pharmaceutically active agent and to methods for treating or preventing or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, *e.g.*, of the skin, ear, or eye, especially for veterinary applications.

WO 2006/012146 A2

**PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND
METHODS OF TREATING OR PREVENTING CONDITIONS USING
SAME**

1. BACKGROUND OF THE INVENTION

5

1.1 FIELD OF THE INVENTION

[0001] The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained- release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, *e.g.*, of the skin, ear, or eye, especially for veterinary applications.

1.2 DESCRIPTION OF RELATED ART

[0002] It is often desirable to administer drugs using controlled- or sustained-release formulations that can maintain at least a minimum therapeutic level, for example, a blood level, of the drug over extended periods of time. These controlled- or sustained- release formulations reduce the frequency of dosing, for enhanced convenience and compliance, and also reduce the severity and frequency of side effects. For example, by maintaining substantially constant blood levels and avoiding blood level fluctuations of the drug, such as are associated with conventional immediate release formulations that are administered several times a day, controlled- or sustained- release formulations can provide a better therapeutic profile than is obtainable with conventional immediate release formulations.

[0003] Known methods for controlled- or sustained-drug release include implanted devices, such as osmotic pumps, and drug dispersed in a biocompatible polymer matrix, which can be implanted, administered orally, or injected. Examples of biocompatible polymers used in such applications include poly(lactic acid) and poly(lactic acid-co-glycolic acid). The polymer typically undergoes slow hydrolysis *in vivo* to continually release the entrapped drug over time. The polymer degradation products are non-toxic and absorbed or metabolized by the body. For example, when the biocompatible polymer is poly(lactic acid) or poly(lactic acid-co-

glycolic acid), the degradation products are the parent acids, lactic acid and glycolic acid, which are absorbed by the body.

[0004] The following patents are representative of those that discuss controlled- or sustained- drug release formulations.

- 5 [0005] U.S. Patent No. 4,814,173 to Song *et al.* discloses a transmembranal pharmaceutical preparation for administering a drug to a mammal comprising a medical grade polysiloxane, a catalyst capable of forming an elastomer, a permeation enhancer, and a biologically active material. The patent disclosure focuses most on transdermal drug delivery systems, particularly transdermal patches.
- 10 [0006] U.S. Patent No. 5,480,649 to Akazawa *et al.* discloses a procaterol-containing preparation for application to the skin having a drug-containing layer provided on a support and comprising a substantially water-free adhesive gel base having as essential components polyacrylic acid, a crosslinking agent, at least one lower alcohol or polyvalent alcohol, and 0.1 to 5% by weight of procaterol or a
- 15 pharmaceutically acceptable salt thereof.

- [0007] International Publication No. WO 03/034988 discloses compositions of a salt of a pharmacologically active compound and a lipophilic counterion and a pharmaceutically acceptable water soluble solvent that are combined together to provide an injectable composition. When injected into an animal, at least a part of
- 20 the composition precipitates to form a depot that slowly releases the pharmacologically active compound over time.

[0008] The following patents are representative of those that discuss topical or otic pharmaceutical compositions.

- [0009] U.S. Patent No. 4,843,096 to Stiefel discloses a topical treatment for
- 25 inflammatory acne using a non-aqueous gel containing 13-cis-retinoic acid. The patent disclosure indicates a preferred gel formulation containing about 0.05 wt% 13-cis-retinoic acid, 3 wt% hydroxypropyl cellulose, about 96.9 wt% ethanol (SDA-40B), and 0.05 wt% butylated hydroxytoluene.

[0010] U.S. Patent No. 4,847,267 to Deckner *et al.* discloses a skin treatment composition and method for inhibiting free radicals in the skin comprising 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid and/or 6-ethoxy-1,2-dihydro-2,2,4-trimethyl quinoline, and optionally a stabilizer of monoethanolamine sulfite or sodium bisulfite. The skin treatment composition also includes water, at least one preservative, preferably, at least one humectant, at least one emulsifier and/or thickener, and optionally may contain one or more chelating agents, one or more gelling agents, one or more emollients, one or more solvents for the free radical inhibitor or deactivator, one or more sunscreen agents, one or more fragrances, and/or one or more coloring agents.

[0011] U.S. Patent No. 5,110,809 to Wang *et al.* discloses a stable anhydrous gel formulations for topical antifungal use containing an imidazole, a steroid, a co-solvent system comprising monohydric and dihydric alcohols, and a hydroxyalkylcellulose gellant.

[0012] International Publication No. WO 00/09117 discloses topical pharmaceutical compositions containing nimesulfide, a non-steroidal anti-inflammatory agent having poor solubility in water.

[0013] U.S. Patent No. 6,146,664 to Siddiqui discloses stable compositions of ascorbic acid in a non-aqueous or substantially anhydrous silicone vehicle containing substantially no environmental oxygen. The ascorbic acid is present as insoluble particles in the polyorganosiloxane vehicle and has a high degree of bioavailability and effectiveness, for example in topical applications to reduce wrinkles and increase collagen growth and elasticity.

[0014] U.S. Patent No. 6,214,339 to Pellico discloses a treatment for *otitis externa* in cats and dogs that comprises administering a substantially non-aqueous, di-enzymatic therapeutic composition, in a liquid or gel fluid carrier. An illustrative composition contains glucose, glucose oxidase, potassium iodide, and lactoperoxidase in a fluid mixture of glycerol and propylene glycol.

[0015] U.S. Patent No. 6,238,683 to Burnett *et al.* discloses anhydrous compositions for topical delivery of a medicament comprising (A) a penetration enhancer of alcohol and/or propylene glycol, (B) a humectant/solvent of polyethylene glycol, glycerin, sorbitol, and/or xylitol, (C) an anhydrous vehicle, and
5 (D) a medicament.

[0016] The following patents are representative of those that discuss drug-containing compositions that are non-aqueous and/or gelatinous.

[0017] European Patent No. 0 081 896 B1 discloses a waterless thixotropic medicament formulation for administration to animals, especially stable semi-solid
10 formulations of macrolide antibiotics. An exemplary formulation in an essentially anhydrous gel formulation comprising from 0.5-10 wt% of a drug, from 2-25 wt% of a hydroxylated fatty acid ester of glycerin, from 55-97.2 wt% of a glycol or glycerin, and from 0.3-15 wt% of a water-soluble polymer.

[0018] U.S. Patent No. 4,837,008 to Rudy *et al.* discloses a non-aqueous paste or
15 gel dentrifice composition for periodontal applications comprising a water-soluble, non-aqueous vehicle having dispersed therein an orally acceptable organic or inorganic peroxide and a bicarbonate salt.

[0019] U.S. Patent No. 4,837,213 to Caron *et al.* discloses a pharmaceutical vehicle for administering and protecting active substances in the form of an
20 anhydrous gel having a viscosity of at least 540 cps and comprising paraffin oil, at least one fatty acid alkyl ester, and a polyvinyl dimethyl siloxane-type elastomeric silicone as a thickener.

[0020] International Publication No. WO 98/36776 and U.S. Patent No. 6,669,958 to Trager *et al.* both disclose methods and compositions for the treatment of a host
25 suffering from a cellular proliferative disease, wherein antiproliferative agents are administered in a substantially non-aqueous gel vehicle comprising at least one polar solvent in combination with one or more thickening agents.

[0021] U.S. Patent No. 6,018,033 to Chen *et al.* discloses hydrophilic, hydrophobic, and thermoreversible polysaccharide gels, including hydrogels, for

controlled drug delivery. Exemplary gel components copolymers of sacchrose and a (meth)acrylate or of sucrose or a modified sucrose and hydrophobic poly(alkylene oxide) (meth)acrylates. The sucrose can be modified: by reaction of the sucrose with an epoxy acrylate to form a hydrophilic sucrose; by reaction first with methacryloyl chloride and then with acetyl chloride to form a hydrophobic sucrose; or by reaction first with methacryloyl chloride and then with aminocarboxylic acids to form a thermoreversible sucrose.

[0022] U.S. Patent No. 6,436,455 to Hei *et al.* discloses antimicrobial and antiviral compositions containing an oxidizing species that is a reaction product of the combination of a quaternary or protonizable nitrogen compound, an oxidant compound, and a halide source at controlled proportions in an *in situ* aqueous, non-aqueous, gel, aerosol, solid-phase, or powdered preparation.

[0023] U.S. patent application No. US 2004/0197408 discloses formulations of a diblock copolymer having a hydrophobic block and hydrophilic block, an additive selected from an amino acid, and an oligopeptide. The formulations, when admixed with water, form drug delivery vehicles in micellar form.

[0024] There remains a need in the art, however, for drug-containing pharmaceutical compositions, suitable for topical, otic, and ophthalmic applications, that provide controlled- and/or sustained- release of the drug contained therein.

[0025] Citation of any reference in Section 4 of this application is not to be construed that such reference is prior art to the present application.

2. SUMMARY OF THE INVENTION

According to a first aspect of the present invention, there is provided a pharmaceutical composition comprising:

a solvent comprising of glycerol formal;

hydroxypropyl methylcellulose; and

an antibacterial agent, an antifungal agent, and a steroid,

wherein the antibacterial agent, antifungal agent, and steroid are dissolved in the solvent and the pharmaceutical composition is in the form of a gel.

According to a second aspect of the present invention, there is provided a pharmaceutical composition comprising:

a solvent comprising a first organic solvent selected from the group consisting of glycerol formal, ethyl lactate, and a mixture thereof;

hydroxypropyl methylcellulose in an amount ranging from about 1 to about 4 weight percent of the composition; and

an antibacterial agent, an antifungal agent, and a steroid,
wherein the antibacterial agent, antifungal agent, and steroid are dissolved in the solvent;
and the pharmaceutical composition is in the form of a gel.

According to a third aspect of the present invention, there is provided a pharmaceutical
5 composition comprising:

poly(ethylene glycol);
a cross-linked poly(acrylic acid) polymer; and
a pharmaceutically active agent,

wherein the poly(acrylic acid) polymer is present in an amount ranging from about 0.2 to
10 about 0.6 wt% of the pharmaceutical composition, the pharmaceutically active agent is dissolved in
the poly(ethylene glycol), and the pharmaceutical composition is in the form of a gel.

According to a fourth aspect of the present invention, there is provided a method of treating
or preventing a condition in an animal comprising topically, optically, or ophthalmically
administering a therapeutically effective amount of the pharmaceutical composition of the first,
15 second or third aspect.

According to a fifth aspect of the present invention, there is provided use of a pharmaceutical
composition according to first, second or third aspect for the manufacture of a medicament for
treating or preventing a condition in an animal.

[0026] The invention relates to a pharmaceutical composition comprising: (i) a first organic
20 solvent selected from the group consisting of glycerol formal, ethyl lactate, and a mixture thereof;
(ii) hydroxypropyl methylcellulose; and (iii) a pharmaceutically active agent, wherein the
pharmaceutical composition is the form of a gel. Optionally, the pharmaceutical composition may
further comprise a second organic solvent selected from the group consisting of glycerol, propylene
glycol, poly(ethylene glycol), and mixtures thereof.

25

[0027] The invention also relates to a pharmaceutical composition comprising: (i) poly(ethylene glycol); (ii) a poly(acrylic acid) polymer; and (iii) a pharmaceutically active agent, wherein the pharmaceutical composition is in the form of a gel.

Optionally, the pharmaceutical composition may further comprise an organic solvent
5 selected from the group consisting of glycerol, propylene glycol, poly(ethylene glycol), and mixtures thereof.

[0028] The invention further relates to a method for treating or preventing a condition in an animal comprising topically, otically, or ophthalmically administering a therapeutically effective amount of a pharmaceutical composition of
10 the invention. In one embodiment, the pharmaceutical composition of the invention is administered to a human, while in another embodiment the pharmaceutical composition of the invention is administered to a non-human animal.

[0029] The invention further relates to a kit containing a pharmaceutical composition of the invention.

15 [0030] These and other features and advantages of the present invention will become apparent from the remainder of the disclosure, in particular the following Detailed Description of the Preferred Embodiments, all of which illustrate by way of example the principles of the invention.

3. BRIEF DESCRIPTION OF THE DRAWINGS

20 [0031] Not Applicable.

4. DETAILED DESCRIPTION OF THE INVENTION

4.1 Definitions

[0032] As used herein, the term "gel" means a material having an average viscosity of at least about 1,000 centipoise ("cps"), preferably at least about 2,000
25 cps, more preferably at least about 5,000 cps, even more preferably at least about 7,500 cps, and most preferably at least about 10,000 cps, but less than about 100,000 cps, preferably less than about 75,000 cps, at 25°C. Typically, a gel exhibits quiescent and/or dynamic interaction between its components, *e.g.*, in the form of

association complexes, which are generally reversible by application of force (*e.g.*, shear) and/or temperature to achieve flow.

[0033] As used herein, the term “polymer” means a macromolecule made up of a series of at least about 10, and preferably more, repeat units linked together. Typical
5 polymers also have a number average molecular weight of more than about 500 g/mol. The polymer can be a homopolymer (only one type of repeat unit), a copolymer (two or more types of repeat units), a blend of homopolymers, a blend of copolymers, or a blend of one or more homopolymers and one or more copolymers.

[0034] As used herein, the term “organic solvent” means any organic compound,
10 or a mixture of organic compounds, that is a liquid at or above about 20°C, preferably at or above about 10°C, more preferably at or above about 0°C, and most preferably at or above about -10°C. Typical organic solvents have a molecular weight of not more than about 500 g/mol and often less than about 100 g/mol. Preferred organic solvents are compounds that, when administered to an animal, do
15 not significantly induce undue adverse effects such as excessive toxicity, irritation, or allergic response (*i.e.*, “pharmaceutically acceptable organic solvents”) commensurate with a reasonable benefit/risk ratio.

[0035] As used herein, the term “pharmaceutically active agent” means a compound that causes a pharmacological effect in an animal. Typically, the
20 pharmacological effect is treating or preventing a condition in an animal. A pharmaceutically active agent can advantageously include a drug in its biologically active form, a pro-drug in a form such that the biologically active drug form is created *in vivo* in the animal, a drug metabolite, a pharmaceutically acceptable salt or ester of a biologically active drug, another therapeutically acceptable form of a
25 biologically active drug, or some combination thereof.

[0036] The term “animal,” as used herein, includes, but is not limited to, cow, horse, sheep, pig, ungulate, chimpanzee, monkey, baboon, chicken, turkey, mouse, rabbit, rat, guinea pig, dog, cat, and human.

[0037] The term "condition," as used herein, means an interruption, cessation, or disorder of a bodily function, system, or organ, and includes diseases, defects, and disorders. Representative conditions include, but are not limited to, infections such as bacterial, viral, fungal, yeast, and parasitic infections; diseases such as cancer; inflammation; diabetes; and organ failure.

[0038] The terms "effective amount" and "therapeutically effective amount," as used herein, mean an amount sufficient for treating or preventing or preventing a condition in an animal.

[0039] The phrases "treating," "treatment of," and the like, include the amelioration or cessation of a specified condition.

[0040] The phrases "preventing," "prevention of," and the like, include the avoidance of the onset of a condition.

[0041] The phrase "pharmaceutically acceptable salt," as used herein, is a salt formed from an acid and a basic nitrogen group of a pharmaceutically active agent. Illustrative salts include, but are not limited, to sulfate; citrate; acetate; oxalate; chloride; bromide; iodide; nitrate; bisulfate; phosphate; acid phosphate; isonicotinate; lactate; salicylate; acid citrate; tartrate; oleate; tannate; pantothenate; bitartrate; ascorbate; succinate; maleate; gentisinate; fumarate; gluconate; glucaronate; saccharate; formate; benzoate; glutamate; methanesulfonate; ethanesulfonate; benzenesulfonate; p-toluenesulfonate; pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)); and salts of fatty acids such as caproate, laurate, myristate, palmitate, stearate, oleate, linoleate, and linolenate salts. The term "pharmaceutically acceptable salt" also refers to a salt prepared from a pharmaceutically active agent having an acidic functional group, such as a carboxylic acid functional group, and a pharmaceutically acceptable inorganic or organic base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia; and organic amines. Representative organic amines include, but are not limited to, unsubstituted or hydroxy-substituted mono-, di-, or trialkylamines;

dicyclohexylamine; tributyl amine; pyridine; N-methyl,N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-hydroxy-lower alkyl amines) such as mono-, bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, and N, N,-di-lower alkyl-N-(hydroxy lower alkyl)-
5 amines (such as N,N,-dimethyl-N-(2-hydroxyethyl)amine or N,N,-dialkyl-N-tris-(2-hydroxyethyl)amines); N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.

[0042] The phrases “substantially no,” “substantially not,” and “substantially free of,” as used herein, mean less than about 5 percent by weight, preferably less than
10 about 1 percent by weight, more preferably less than about 0.5 percent by weight, most preferably less than about 0.1 percent by weight. For example, the phrase “a pharmaceutical composition substantially free of water” means that the amount of water in the pharmaceutical composition is less than about 5 percent by weight, preferably less than about 1 percent by weight, more preferably less than about 0.5
15 percent by weight, most preferably less than about 0.1 percent by weight of the pharmaceutical composition.

4.2 **Pharmaceutical composition comprising hydroxypropyl methylcellulose; glycerol formal, ethyl lactate, or a mixture thereof; and a pharmaceutically active agent**

20

[0043] The present invention relates to a pharmaceutical composition comprising:
(i) a first organic solvent selected from the group consisting of glycerol formal, ethyl lactate, and a mixture thereof; (ii) hydroxypropyl methylcellulose; and (iii) a therapeutically effective amount of a pharmaceutically active agent, wherein the
25 pharmaceutical composition is in the form of a gel.

[0044] In one embodiment, the pharmaceutical composition further comprises a second organic solvent selected from the group consisting of glycerol, propylene glycol, poly(ethylene glycol), and a mixture thereof.

[0045] The hydroxypropyl methylcellulose has an average molecular weight
30 sufficiently high such that the hydroxypropyl methylcellulose, the organic

solvent(s), and the pharmaceutically active agent form a gel when they are combined.

[0046] In one embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is at least about 7,500 g/mol.

5 [0047] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is at least about 10,000 g/mol.

[0048] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is at least about 20,000 g/mol.

10 [0049] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is at least about 30,000 g/mol.

[0050] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is from about 7,500 to about 1,000,000 g/mol.

[0051] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is from about 10,000 to about 1,000,000 g/mol.

15 [0052] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is from about 20,000 to about 1,000,000 g/mol.

[0053] In another embodiment, the number average molecular weight of the hydroxypropyl methylcellulose is from about 30,000 to about 1,000,000 g/mol.

20 [0054] In one embodiment, the hydroxypropyl methylcellulose may be crosslinked. Without wishing to be bound by theory, it is believed that crosslinking the hydroxypropyl methylcellulose facilitates gel formation.

[0055] In another embodiment, the hydroxypropyl methylcellulose is substantially not crosslinked.

25 [0056] In one embodiment, the amount of hydroxypropyl methylcellulose in the pharmaceutical composition of the invention ranges from about 1 to about 10 wt% of the pharmaceutical composition.

[0057] In another embodiment, the amount of hydroxypropyl methylcellulose in the pharmaceutical composition of the invention ranges from about 2 to about 6 wt% of the pharmaceutical composition.

5 [0058] In another embodiment, the amount of hydroxypropyl methylcellulose in the pharmaceutical composition of the invention ranges from about 2 to about 5 wt% of the pharmaceutical composition.

[0059] In another embodiment, the amount of hydroxypropyl methylcellulose in the pharmaceutical composition of the invention ranges from about 3 to about 6 wt% of the pharmaceutical composition.

10 [0060] In another embodiment, the amount of hydroxypropyl methylcellulose in the pharmaceutical composition of the invention ranges from about 3 to about 4 wt% of the pharmaceutical composition.

[0061] By varying the amount of hydroxypropyl methylcellulose, the viscosity of the pharmaceutical composition can be varied. Typically, the greater the amount of
15 hydroxypropyl methylcellulose, the higher the resulting viscosity of the pharmaceutical composition.

[0062] One of ordinary skill in the art will recognize, however, that the amount of hydroxypropyl methylcellulose in the pharmaceutical compositions of the invention can vary widely depending on, *inter alia*, its molecular weight, the organic
20 solvent(s) present, the pharmaceutically active agent present, and/or other additional components present in the pharmaceutical composition.

[0063] The first organic solvent and the optional second organic solvent can include small amounts of impurities. Typically, the organic solvent(s) has(have) a purity of greater than about 95 percent by weight, preferably greater than about 97
25 percent by weight, more preferably greater than about 98 percent by weight, and most preferably greater than about 99 percent by weight.

[0064] In one embodiment, the first organic solvent comprises glycerol formal. In another embodiment, the first organic solvent is glycerol formal.

[0065] In another embodiment, the first organic solvent comprises ethyl lactate.
In another embodiment, the first organic solvent is ethyl lactate.

[0066] In one embodiment, the second organic solvent comprises poly(ethylene glycol). In another embodiment, the poly(ethylene glycol) has a molecular weight
5 not more than about 500 g/mol. In another embodiment, the poly(ethylene glycol) has a molecular weight of about 400 g/mol.

[0067] In another embodiment, the second organic solvent is poly(ethylene glycol). In another embodiment, the poly(ethylene glycol) has a molecular weight not more than about 500 g/mol. In another embodiment, the poly(ethylene glycol)
10 has a molecular weight of about 400 g/mol.

[0068] In another embodiment, the second organic solvent comprises propylene glycol. In another embodiment, the second organic solvent is propylene glycol.

[0069] In another embodiment, the second organic solvent comprises glycerol. In another embodiment, the second organic solvent is glycerol.

15 [0070] The total amount of organic solvent (*i.e.*, the first organic solvent plus the second organic solvent, if present) typically ranges from about 10 to about 98 wt% of the pharmaceutical composition.

[0071] In another embodiment, the total amount of organic solvent is from about 20 to about 98 wt% of the pharmaceutical composition.

20 [0072] In another embodiment, the total amount of organic solvent is from about 25 to about 90 wt% of the pharmaceutical composition.

[0073] In another embodiment, the total amount of organic solvent is from about 35 to about 95 wt% of the pharmaceutical composition.

[0074] In another embodiment, the total amount of organic solvent is from about
25 45 to about 90 wt% of the pharmaceutical composition.

[0075] In another embodiment, the total amount of organic solvent is from about 50 to about 95 wt% of the pharmaceutical composition.

[0076] In another embodiment, the total amount of organic solvent is from about 60 to about 90 wt% of the pharmaceutical composition.

5 [0077] In another embodiment, the total amount of organic solvent is from about 55 to about 95 wt% of the pharmaceutical composition.

[0078] In another embodiment, the total amount of organic solvent is from about 70 to about 98 wt% of the pharmaceutical composition.

10 [0079] The amount of the second organic solvent, when present, can be up to about 50 wt% of the total amount of organic solvent.

[0080] In one embodiment, the pharmaceutical composition contains substantially no second organic solvent.

[0081] In another embodiment, the amount of the second organic solvent is up to about 40 wt% of the total amount of organic solvent.

15 [0082] In another embodiment, the amount of the second organic solvent is up to about 30 wt% of the total amount of organic solvent.

[0083] In another embodiment, the amount of the second organic solvent is up to about 20 wt% of the total amount of organic solvent.

20 [0084] In another embodiment, the amount of the second organic solvent is up to about 10 wt% of the total amount of organic solvent.

[0085] In another embodiment, the amount of the second organic solvent is up to about 5 wt% of the total amount of organic solvent.

[0086] In another embodiment, the amount of the second organic solvent is from about 5 wt% to about 40 wt% of the total amount of organic solvent.

[0087] In another embodiment, the amount of the second organic solvent is from about 10 wt% to about 30 wt% of the total amount of organic solvent.

[0088] In another embodiment, the amount of the second organic solvent is from about 5 wt% to about 25 wt% of the total amount of organic solvent.

5 [0089] In another embodiment, the amount of the second organic solvent is from about 10 wt% to about 20 wt% of the total amount of organic solvent.

[0090] In one embodiment, the first organic solvent is glycerol formal and the second organic solvent is glycerol.

10 [0091] In another embodiment, the glycerol formal and glycerol are present in the pharmaceutical composition in a volume ratio of about 90:10.

[0092] In one embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, and glycerol formal.

15 [0093] In another embodiment, the pharmaceutical composition comprises from about 0.2 to about 7 wt% hydroxypropyl methyl cellulose, from about 3 to about 20 wt% glycerol, and from about 65 to about 86 wt% glycerol formal.

[0094] In another embodiment, the pharmaceutical composition comprises about 4 wt% hydroxypropyl methyl cellulose, from about 9 to about 10 wt% glycerol, and from about 78 to about 85 wt% glycerol formal.

20 [0095] In another embodiment, the first organic solvent is ethyl lactate and the second organic solvent is glycerol.

[0096] In another embodiment, the ethyl lactate and glycerol are present in the pharmaceutical composition in a volume ratio from about 95:5 to about 75:25.

[0100] In one embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, and ethyl lactate.

[0101] In another embodiment, the pharmaceutical composition comprises from about 0.2 to about 7 wt% hydroxypropyl methyl cellulose, from about 3 to about 20 wt% glycerol, and from about 65 to about 86 wt% ethyl lactate.

[0102] In another embodiment, the pharmaceutical composition comprises about 4 wt% hydroxypropyl methyl cellulose, from about 9 to about 10 wt% glycerol, and from about 78 to about 85 wt% ethyl lactate.

[0103] Any pharmaceutically active agent can be used in this pharmaceutical composition of the invention.

[0104] The pharmaceutical composition of the invention can be prepared by simply adding the pharmaceutically active agent(s) to the glycerol formal and/or ethyl lactate, as well as the second organic solvent, if present (typically about 90% of the total amount of the organic solvent desired in the final pharmaceutical composition), and agitating the resulting mixture until the pharmaceutically active agent(s) dissolve(s). One or more optional additive components can simultaneously and/or sequentially be added and the mixture agitated until the additive component(s) dissolve(s). HPMC is then added followed by additional solvent, to provide the desired concentration of the pharmaceutically active agent(s) in the pharmaceutical composition. Optionally, the solvent is warmed to a temperature of about 40°C before the HPMC is added. Once all the desired components are added, the resulting solution can then be homogenized, *e.g.*, for about 1 to about 10 minutes, to form a uniform pharmaceutical composition. Without being bound to theory, it is believed that longer homogenization time and higher homogenization speeds result in a pharmaceutical composition having reduced viscosity. Following homogenization, the composition can be allowed to sit undisturbed until a gel is formed. One skilled in the art will readily recognize, however, that modifications to the above-described method for preparing the pharmaceutical compositions of the invention are possible, for example the order of adding the components to the solvent(s) can be changed.

4.3 Pharmaceutical composition comprising poly(acrylic acid), poly(ethylene glycol) and a pharmaceutically active agent

[0105] Another aspect of the present invention relates to a pharmaceutical composition comprising: (i) poly(ethylene glycol); (ii) a poly(acrylic acid) polymer; and (iii) a therapeutically effective amount of a pharmaceutically active agent, wherein the pharmaceutical composition is in the form of a gel.

5 [0106] In one embodiment, the pharmaceutical compositions further comprises an organic solvent selected from the group consisting of glycerol, propylene glycol, and a mixture thereof.

[0107] The poly(acrylic acid) polymer used in the pharmaceutical compositions of the invention has an average molecular weight sufficiently high such that the
10 poly(acrylic acid) polymer, the poly(ethylene glycol), the optional organic solvents, and the pharmaceutically active agent form a gel when they are combined.

[0108] In one embodiment, the number average molecular weight of the poly(acrylic acid) polymer is at least about 7,500 g/mol.

[0109] In another embodiment, the number average molecular weight of the
15 poly(acrylic acid) polymer is at least about 10,000 g/mol.

[0110] In another embodiment, the number average molecular weight of the poly(acrylic acid) polymer is at least about 20,000 g/mol.

[0111] In another embodiment, the number average molecular weight of the poly(acrylic acid) polymer is at least about 30,000 g/mol.

20 [0112] In another embodiment, the number average molecular weight of the poly(acrylic acid) polymer is from about 7,500 to about 1,000,000 g/mol.

[0113] In another embodiment, the number average molecular weight of the poly(acrylic acid) polymer is from about 10,000 to about 1,000,000 g/mol.

[0114] In another embodiment, the number average molecular weight of the
25 poly(acrylic acid) polymer is from about 20,000 to about 1,000,000 g/mol.

[0115] In another embodiment, the number average molecular weight of the poly(acrylic acid) polymer is from about 30,000 to about 1,000,000 g/mol.

[0116] In one embodiment, the poly(acrylic acid) polymer used in the pharmaceutical compositions of the invention is substantially not crosslinked.

5 [0117] In another embodiment, the polymer used in the pharmaceutical compositions of the invention comprises crosslinked poly(acrylic acid), *e.g.*, such as commercially available under the tradename Carbomer™ or Carbopol® from Noveon, Inc., of Cleveland, OH. In another embodiment, the polymer(s) used in the pharmaceutical compositions according to the invention comprises Carbomer™ 941
10 or Carbopol® 941. Without wishing to be bound by theory, it is believed that certain crosslinked polymers facilitate gel formation.

[0118] In one embodiment, the amount of poly(acrylic acid) polymer ranges from about 0.1 to about 2 wt% of the pharmaceutical composition.

15 [0119] In another embodiment, the amount of poly(acrylic acid) polymer ranges from about 0.1 to about 1 wt% of the pharmaceutical composition.

[0120] In another embodiment, the amount of poly(acrylic acid) polymer ranges from about 0.2 to about 0.6 wt% of the pharmaceutical composition.

[0121] In another embodiment, the amount of poly(acrylic acid) polymer is about 0.4 wt% of the pharmaceutical composition.

20 [0122] One of ordinary skill in the art will recognize, however, that the amount of poly(acrylic acid) polymer in the pharmaceutical compositions of the invention can vary widely depending on, *inter alia*, the level of polymer crosslinking, the molecular weights of the polymer, the molecular weights of the poly(ethylene glycol), the optional organic solvent(s) present, the pharmaceutically active agent
25 present, and/or other additional components present in the pharmaceutical composition.

[0123] The poly(ethylene glycol) and the optional organic solvent can include small amounts of impurities. Typically, poly(ethylene glycol) and the optional

organic solvent have a purity of greater than about 95 percent by weight, preferably greater than about 97 percent by weight, more preferably greater than about 98 percent by weight, and most preferably greater than about 99 percent by weight.

[0124] In another embodiment, the optional organic solvent is present and
5 comprises propylene glycol. In another embodiment, the optional organic solvent is present and is propylene glycol.

[0125] In another embodiment, the optional organic solvent is present and comprises glycerol. In another embodiment, the optional organic solvent is present and is glycerol.

10 [0126] The total amount of solvent (*i.e.*, poly(ethylene glycol) plus the optional organic solvent) typically ranges from about 10 to about 98 wt% of the pharmaceutical composition.

[0127] In another embodiment, the total amount of solvent is from about 20 to about 98 wt% of the pharmaceutical composition.

15 [0128] In another embodiment, the total amount of solvent is from about 25 to about 90 wt% of the pharmaceutical composition.

[0129] In another embodiment, the total amount of solvent is from about 35 to about 95 wt% of the pharmaceutical composition.

20 [0130] In another embodiment, the total amount of solvent is from about 45 to about 90 wt% of the pharmaceutical composition.

[0131] In another embodiment, the total amount of solvent is from about 50 to about 95 wt% of the pharmaceutical composition.

[0132] In another embodiment, the total amount of solvent is from about 60 to about 90 wt% of the pharmaceutical composition.

25 [0133] In another embodiment, the total amount of solvent is from about 55 to about 95 wt% of the pharmaceutical composition.

[0134] In another embodiment, the total amount of solvent is from about 70 to about 98 wt% of the pharmaceutical composition.

[0135] The amount of the optional organic solvent, when present, can be up to about 50 wt% of the total amount of solvent.

5 [0136] In one embodiment, the pharmaceutical composition contains substantially no optional organic solvent.

[0137] In another embodiment, the amount of the optional organic solvent is up to about 40 wt% of the total amount of solvent.

10 [0138] In another embodiment, the amount of the optional organic solvent is up to about 30 wt% of the total amount of solvent.

[0139] In another embodiment, the amount of the optional organic solvent is up to about 20 wt% of the total amount of solvent.

[0140] In another embodiment, the amount of the optional organic solvent is up to about 10 wt% of the total amount of solvent.

15 [0141] In another embodiment, the amount of the optional organic solvent is up to about 5 wt% of the total amount of solvent.

[0142] In another embodiment, the amount of the optional organic solvent is from about 5 wt% to about 40 wt% of the total amount of solvent.

20 [0143] In another embodiment, the amount of the optional organic solvent is from about 10 wt% to about 30 wt% of the total amount of solvent.

[0144] In another embodiment, the amount of the optional organic solvent is from about 5 wt% to about 25 wt% of the total amount of solvent.

[0145] In another embodiment, the amount of the optional organic solvent is from about 10 wt% to about 20 wt% of the total amount of solvent.

[0146] In one embodiment, the poly(ethylene glycol) has an average molecular weight of about 500 g/mol.

[0147] In another embodiment, the poly(ethylene glycol) has an average molecular weight of about 400 g/mol.

5 [0148] In another embodiment, the poly(ethylene glycol) has an average molecular weight of about 400 g/mol, glycerol is the organic solvent, and the poly(ethylene glycol) and glycerol are present in the pharmaceutical composition in a volume ratio of about 80:20.

[0149] In one embodiment, the pharmaceutical composition comprises
10 poly(acrylic acid), glycerol, and poly(ethylene glycol).

[0150] In another embodiment, the pharmaceutical composition comprises a crosslinked poly(acrylic acid), glycerol, and poly(ethylene glycol) having an average molecular weight of about 400 g/mol.

[0151] In another embodiment, the pharmaceutical composition comprises from
15 about 0.1 to about 2 wt% crosslinked poly(acrylic acid), from about 5 to about 30 wt% glycerol, and from about 60 to about 93 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol.

[0152] In another embodiment, the pharmaceutical composition comprises from
20 about 0.1 to about 1 wt% crosslinked poly(acrylic acid), from about 5 to about 30 wt% glycerol, and from about 60 to about 93 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol.

[0153] In another embodiment, the pharmaceutical composition comprises about
25 0.5 wt% crosslinked poly(acrylic acid), from about 19 to about 20 wt% glycerol, and from about 73 to about 79 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol.

[0154] Any pharmaceutically active agent can be used in the pharmaceutical compositions according to the invention. However, it is preferred that the pharmaceutically active agent not have more than one amino group. Without

wishing to be bound by theory, it is believed that pharmaceutically active agents having more than one amino group can cause additional crosslinking with the poly(acrylic acid) polymer, resulting in a gel too viscous for the desired application.

[0155] The pharmaceutical composition of the invention can be prepared by simply adding the pharmaceutically active agent(s) to the poly(ethylene glycol) and the optional organic solvent, if present (typically about 90% of the total amount of the solvent desired in the final pharmaceutical composition), and agitating the resulting mixture until the pharmaceutically active agent(s) dissolve(s). One or more optional additive components can simultaneously and/or sequentially be added and the mixture agitated until additive component(s) dissolve(s). The poly(acrylic acid) polymer can then be added followed by additional solvent, to provide the desired concentration of the pharmaceutically active agent(s) in the pharmaceutical composition. Optionally, the solvent is warmed to a temperature of about 40°C before the poly(acrylic acid) polymer is added. Once all the desired components are added, the resulting solution can then be homogenized, *e.g.*, for about 1 to about 10 minutes, to form a uniform pharmaceutical composition. Without being bound to theory, it is believed that longer homogenization time and higher homogenization speeds result in a pharmaceutical composition having reduced viscosity. Following homogenization, the composition can be allowed to sit undisturbed until a gel is formed. One skilled in the art, however, will readily recognize that modifications to the above-described method for preparing the pharmaceutical compositions of the invention are possible, for example the order of adding the components to the solvent(s) can be changed.

4.4 Pharmaceutically active agents

[0156] In one embodiment, the pharmaceutically active agent is present as a pharmaceutically acceptable salt of the pharmaceutically active agent.

[0157] In another embodiment, the pharmaceutically active agent is a zwitterion.

[0158] In another embodiment, the pharmaceutically active agent is a basic compound.

[0159] In another embodiment, the pharmaceutically active agent is an acidic compound.

[0160] In another embodiment, the pharmaceutically active agent is a neutral compound.

5 [0161] The amount of pharmaceutically active agent in the pharmaceutical compositions typically ranges from about 0.01 to about 5 wt% of the pharmaceutical composition.

[0162] In another embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 0.05 to about 5 wt% of the
10 pharmaceutical composition.

[0163] In another embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 0.1 to about 3 wt% of the pharmaceutical composition.

[0164] In another embodiment, the amount of pharmaceutically active agent in the
15 pharmaceutical composition is from about 0.3 to about 2 wt% of the pharmaceutical composition.

[0165] In another embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 0.5 to about 4 wt% of the pharmaceutical composition.

20 [0166] In one embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 1 to about 5 wt% of the pharmaceutical composition.

[0167] In one embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 0.2 to about 2.5 wt% of the
25 pharmaceutical composition.

[0168] In another embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 0.05 to about 1.5 wt% of the pharmaceutical composition.

[0169] In another embodiment, the amount of pharmaceutically active agent in the pharmaceutical composition is from about 0.01 to about 1 wt% of the pharmaceutical composition.

[0170] One of ordinary skill in the art will recognize, however, that the amount of pharmaceutically active agent in the pharmaceutical compositions according to the invention can vary widely depending on the pharmaceutically active agent and any other components present in the pharmaceutical composition.

[0171] Examples of active agents useful as the active agent component of the composition according to the invention include, but are not limited to, α -adrenergic agonists, β -adrenergic agonists, α -adrenergic blockers, β -adrenergic blockers, aldose reductase inhibitors, anabolics, analgesics (narcotic and non-narcotic), androgens, anesthetics, anorexics, anthelmintics (*e.g.*, cestode, nematode, onchocerca, schistosoma, and the like), anti-allergics, anti-ameboics, anti-androgens, anti-anginals, anti-arrhythmics, anti-arteriosclerotics, anti-arthritis, antibiotics and other antibacterials, anti-cholinergics, anti-convulsants, anti-depressants, anti-diabetics agents, anti-diarrheals, anti-diuretics, anti-estrogens, antifungals, anti-yeast agents, anti-glaucomas, anti-gonadotropins, anti-gout agents, anti-histaminics, anti-hyperlipoproteinemics, anti-hypertensives, anti-hyperthyroid agents, anti-hypertrophy agents, anti-hypotensives, anti-hypothyroid agents, antiinflammatories, anti-malarials, antimicrobials, anti-migraine agents, anti-nausea agents, anti-neoplastics, antioxidants, antiparasitic agents, anti-parkinsonian agents, anti-pheochromocytoma agents, anti-pneumocytis agents, antiproliferative agents, anti-protozoals (*e.g.*, leishmania, trichomonas, trypanosoma, and the like), anti-pruritic agents, anti-psoratic agents, anti-psychotic agents, anti-pyretics, anti-rheumatics, anti ricketts agents, anti-seborrheic agents, antiseptics, anti-spasmodic agents, anti-thrombotic agents, antitussives, anti-ulcer agents, anti-urolithic agents, anti-venins, antivirals, anxiolytics, benzodiazepine antagonists, bronchodilators, calcium channel blockers, calcium regulators, cardiotonics, chelating agents, chemotherapeutics,

cholecystokinin antagonists, cholelitholytic agents, choleretics, cholinergics, cholinesterase inhibitors, cholinesterase reactivators, central nervous system stimulants and agents, decongestants, diuretics, dopamine receptor agonists, drugs for treating or preventing pain, ectoparasitocides, enzymes, enzyme inducers, 5 estrogens, gastric secretion inhibitors, glucocorticoids, gonad-stimulating principles, gonadotropic hormones, growth hormones, growth hormone releasing factors, growth stimulants, hemolytics, heparin agonists, hepatoprotectants, hypnotics, immune system boosters, immunomodulators, immunosuppressants, lactation stimulating hormones, LH-RH stimulating agonists, lipotropics, lupus erythmatosus 10 suppressants, mineral corticoids, miotics, monoamine oxidase inhibitors, mucolytics, muscle relaxants, narcotic antagonists, neuroprotectives, neotropics, ovarian hormones, oxytocics, pepsin inhibitors, peristaltic stimulators, progestrogens, prolactin inhibitors, protoglandins, prostoglandin analogs, protease inhibitors, respiratory stimulants, sclerosing agents, sedatives, steroids, thrombolytics, 15 thyrotropic hormones, transdermal penetration enhancers, uricosurics, vasoconstrictors, vasodilators (*e.g.*, cerebral, coronary, peropheral, and the like), vasoprotectants, vitamins, vitamin source extracts, vulneraries (including, but not limited to, those listed in U.S. Patent No. 5,719,197, the entire disclosure of which is incorporated herein by reference), and combinations thereof. Other additionally or 20 alternately acceptable pharmaceutically active agents can be found, *e.g.*, in U.S. Patent No. 6,221,383, the entire disclosure of which is incorporated herein by reference.

[0172] In one embodiment, the pharmaceutically active agent comprises an antibacterial agent.

25 [0173] In another embodiment, the pharmaceutically active agent comprises an antifungal agent.

[0174] In another embodiment, the pharmaceutically active agent comprises an antiparasitic agent.

[0175] In another embodiment, the pharmaceutically active agent comprises an 30 antiviral agent.

[0176] In another embodiment, the pharmaceutically active agent comprises an anti-yeast agent.

[0177] In another embodiment, the pharmaceutically active agent comprises a steroid.

5 [0178] In another embodiment, the pharmaceutically active agent comprises an antiinflammatory agent.

[0179] Examples of useful antibacterial agents include, but are not limited to, β -lactam antibiotics such as penicillins, amoxicillin, ampicillin, and cephalosporins; macrolide antibiotics such as oleandomycin and erythromycin; tetracyclines such as
10 tetracycline, oxytetracycline, and chlortetracycline; procaine penicillin G; quinolones such as enrofloxacin, nalidixic acid and norfloxacin; sulfonamides; chloramphenicol; florfenicol; thiamphenicol, aminoglycosides such as tobramycin, streptomycin, kanamycin, and gentamycins; nucleoside antibiotics such as polyoxin B; actinorhodine; bacitracin; candicidin A; ceftiofor; clindamycin; cycloheximide;
15 cycloserine; fosfomycin; griseofulvin; metronidazole; monensin; novobiocin; rifampin; streptothricin; tetranactin; tilmicosin; tylosin; actinomycin D; adriamycin; bleomycin B2; glycolipids such as moenomycin A; mitomycin C; nojirimycin; valinomycin; and vancomycin; (See, e.g., Bradford P. Smith, *Large Animal Internal Medicine*, 2nd edn., Mosby, St. Louis, 1996, p. 644, and S. Birchard and R.
20 Sherding, *Saunders Manual of Small Animal Practice*, W.B. Saunders Company, Philadelphia, 1994, p. 739).

[0180] Examples of useful antifungal agents include, but are not limited to amphotericin B, clotrimazole, ketaconazole, miconazole, 5-fluorocytosine, enilconazole, itraconazole, thiabendazole, and iodides (See, e.g., Bradford P. Smith,
25 *Large Animal Internal Medicine*, 2nd edn., Mosby, St. Louis, 1996, p. 576, and S. Birchard and R. Sherding, *Saunders Manual of Small Animal Practice*, W.B. Saunders Company, Philadelphia, 1994, p. 576).

[0181] Examples of useful antiviral agents include, but are not limited to, interferon (*See, e.g.,* Bradford P. Smith, *Large Animal Internal Medicine*, 2nd edn., Mosby, St. Louis, 1996, p. 646).

[0182] Examples of useful anti-yeast agents include, but are not limited to,
5 aminoglycosides such as tobramycin, streptomycin, kanamycin, and gentamicin.

[0183] Examples of useful antiparasitic agents include, but are not limited to nitazoxanide (NTA); benzimidazoles, such as thiabendazole, fenbendazole, mebendazole, oxfendazole, oxibendazole, albendazole, parbendazole, and febantel; tetrahydropyridines such as morantel tartrate/pyrantel pamoate; levamisole,
10 organophosphates such as haloxon, coumaphos, trichlorfon, and dichlorvos; piperazine salts; ivermectin; and phenothiazine (*See, e.g.,* Bradford P. Smith, *Large Animal Internal Medicine*, 2nd edn., Mosby, St. Louis, 1996, p. 1688).

[0184] Examples of useful antiinflammatory agents include, but are not limited to, steroids such as betamethasone; corticosteroids such as dexamethasone;
15 antihistamines; and non-steroidal antiinflammatory drugs such as diclofenac, aspirin, flunixin meglumine, phenylbutazone, and ibuprofen (*See, e.g.,* Bradford P. Smith, *Large Animal Internal Medicine*, 2nd edn., Mosby, St. Louis, 1996, p. 645).

[0185] In one embodiment, there can be multiple pharmaceutically active agents in a single pharmaceutical composition.

20 [0186] In another embodiment, the pharmaceutically active agent comprises the combination of an antibacterial agent, an antifungal agent, and a steroid.

[0187] Effective amounts of these pharmaceutically active agents are known to those skilled in the art. It is well within the skilled artisan's purview to determine each pharmaceutically active agent's optimal effective-amount range.

25 [0188] In one embodiment of the invention, where multiple pharmaceutically active agents are administered to an animal, the effective amount each pharmaceutically active agent is less than its effective amount would be were the other pharmaceutically active agent(s) not administered. In this case, without being

bound by theory, it is believed that multiple pharmaceutically active agents act synergistically to treat or prevent a condition (*e.g.*, a bacterial infection).

[0189] In one embodiment, the pharmaceutically active agent comprises Tobramycin.

5 [0190] In another embodiment, the pharmaceutically active agent comprises Tobramycin decanoic fatty acid salt.

[0191] In another embodiment, the pharmaceutically active agent comprises Tobramycin oleic fatty acid salt.

10 [0192] In another embodiment, the pharmaceutically active agent comprises Tobramycin acetic acid salt.

[0193] In another embodiment, the pharmaceutically active agent comprises Terbinafine.

[0194] In another embodiment, the pharmaceutically active agent comprises Terbinafine decanoic fatty acid salt.

15 [0195] In another embodiment, the pharmaceutically active agent comprises Terbinafine oleic fatty acid salt.

[0196] In another embodiment, the pharmaceutically active agent comprises Terbinafine acetic acid salt.

20 [0197] In another embodiment, the pharmaceutically active agent comprises Betamethasone.

[0198] In another embodiment, the pharmaceutically active agent comprises Betamethasone acetate.

[0199] In another embodiment, the pharmaceutically active agent comprises Florfenicol.

[0200] In another embodiment, the pharmaceutically active agent comprises Thiamphenicol.

[0201] In another embodiment, the pharmaceutically active agent comprises Chloramphenicol.

5 [0202] In another embodiment, the pharmaceutically active agent comprises Gentamicin.

[0203] In another embodiment, the pharmaceutically active agent comprises Clotrimazole.

10 [0204] In another embodiment, the pharmaceutically active agent comprises Tilimicosin.

[0205] In another embodiment, the pharmaceutically active agent comprises a Tetracycline compound.

[0206] In another embodiment, the pharmaceutically active agent comprises Ketoconazole.

15 [0207] In another embodiment, the pharmaceutically active agent comprises Diclofenac.

[0208] In another embodiment, the pharmaceutically active agent comprises Flunixin.

20 [0209] In another embodiment, the pharmaceutically active agent comprises Carprofen.

[0210] In another embodiment, the pharmaceutically active agent comprises a Cephalosporin.

[0211] In another embodiment, the pharmaceutically active agent comprises a combination of Tobramycin or a pharmaceutically acceptable salt thereof,
25 Terbinafine or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0212] In another embodiment, the pharmaceutically active agent comprises a combination of Tobramycin decanoic fatty acid salt, Terbinafine decanoic fatty acid salt, and Betamethasone or a pharmaceutically acceptable ester thereof.

5 [0213] In another embodiment, the pharmaceutically active agent comprises from about 0.5 to about 3 wt% of Tobramycin decanoic fatty acid salt, from about 0.5 to about 3 wt% of Terbinafine decanoic fatty acid salt, and from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0214] In another embodiment, the pharmaceutically active agent comprises about 1 wt% of Tobramycin decanoic fatty acid salt, about 1 wt% of Terbinafine decanoic fatty acid salt, and about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0215] In another embodiment, the pharmaceutically active agent comprises a combination of Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0216] In another embodiment, the pharmaceutically active agent comprises a combination of Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine oleic fatty acid salt, and Betamethasone or a pharmaceutically acceptable ester thereof.

20 [0217] In another embodiment, the pharmaceutically active agent comprises from about 0.5 to about 3 wt% of Florfenicol or a pharmaceutically acceptable ester thereof, from about 0.5 to about 3 wt% of Terbinafine oleic fatty acid salt, and from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

25 [0218] In another embodiment, the pharmaceutically active agent comprises about 1 wt% of Florfenicol or a pharmaceutically acceptable ester thereof, about 1 wt% of Terbinafine oleic fatty acid salt, and about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0219] In another embodiment, the pharmaceutically active agent comprises Gentamycin or a pharmaceutically acceptable salt thereof, Clotrimazole or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

5 [0220] In another embodiment, the pharmaceutically active agent comprises from about 0.5 to about 3 wt% of Gentamycin or a pharmaceutically acceptable salt thereof, from about 0.5 to about 3 wt% of Clotrimazole or a pharmaceutically acceptable salt thereof, and from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

10 [0221] In another embodiment, the pharmaceutically active agent comprises about 1 wt% of Gentamycin or a pharmaceutically acceptable salt thereof, about 1 wt% of Clotrimazole or a pharmaceutically acceptable salt thereof, and about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

15 [0222] In one embodiment, the pharmaceutically active agent has an amine moiety and is present in the pharmaceutical composition of the invention as a fatty acid salt ("FAS") by converting the amine moiety to an ammonium cation whose counterion is a fatty acid moiety such as those described in International Publication No. WO 03/034988 A2, the entire disclosure of which is incorporated herein in its entirety.

[0223] Without being bound to theory, it is believed that a FAS of a
20 pharmaceutically active agent provides additional sustained- or controlled-release of the pharmaceutically active agent (as reflected in more steady blood levels as a function of time). Without wishing to be bound by theory, it is believed that the additional sustained- or controlled-release of the pharmaceutically active agent obtained when using a FAS of a pharmaceutically active agent is because the FAS of
25 a pharmaceutically active agent is less soluble in water than the pharmaceutically active agent itself or other non-fatty acid salt of the pharmaceutically active agent and, accordingly, is absorbed by the animal more slowly.

4.5 Optional pharmaceutical composition additives

[0224] The present pharmaceutical compositions can optionally comprise a suitable amount of a pharmaceutically acceptable preservative, if desired, so as to provide additional protection against microbial growth.

5 [0225] Examples of preservatives useful in the pharmaceutical compositions of the invention include, but are not limited to, potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chlorides (*e.g.*, benzethonium chloride).

10 [0226] In one embodiment, any additional components added to the pharmaceutical compositions of the invention are designated as GRAS (“generally recognized as safe”) by the FDA for use or consumption by animals.

[0227] In another embodiment, any additional components added to the pharmaceutical compositions of the invention are designated as GRAS by the FDA
15 for use or consumption by humans.

[0228] In one embodiment, any additional components added to the pharmaceutical compositions of the invention are sterile when administered to an animal.

4.6 The pharmaceutical compositions

20 [0229] In one embodiment, the pharmaceutical composition has a viscosity of greater than about 1,000 cps at about 25°C.

[0230] In another embodiment, the pharmaceutical composition has a viscosity of greater than about 2,000 cps at about 25°C.

[0231] In another embodiment, the pharmaceutical composition has a viscosity of
25 greater than about 5,000 cps at about 25°C.

[0232] In another embodiment, the pharmaceutical composition has a viscosity of greater than about 10,000 cps at about 25°C.

[0233] In another embodiment, the pharmaceutical composition has a viscosity of greater than about 15,000 cps at about 25°C.

[0234] In another embodiment, the pharmaceutical composition has a viscosity of greater than about 20,000 cps at about 25°C.

5 [0235] In another embodiment, the pharmaceutical composition has a viscosity of greater than about 25,000 cps at about 25°C.

[0236] Typically, the pharmaceutical composition has a viscosity of less than about 100,000 cps at about 25°C.

10 [0237] In one embodiment, the pharmaceutical composition has a viscosity of less than about 75,000 cps at about 25°C.

[0238] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 1,000 cps to about 100,000 cps at about 25°C.

[0239] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 2,000 cps to about 100,000 cps at about 25°C.

15 [0240] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 5,000 cps to about 100,000 cps at about 25°C.

[0241] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 10,000 cps to about 100,000 cps at about 25°C.

20 [0242] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 20,000 cps to about 100,000 cps at about 25°C.

[0243] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 25,000 cps to about 100,000 cps at about 25°C.

[0244] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 2,000 cps to about 75,000 cps at about 25°C.

[0245] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 5,000 cps to about 75,000 cps at about 25°C.

[0246] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 10,000 cps to about 75,000 cps at about 25°C.

5 [0247] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 20,000 cps to about 75,000 cps at about 25°C.

[0248] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 25,000 cps to about 75,000 cps at about 25°C.

10 [0249] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 1,000 cps to about 25,000 cps at about 25°C.

[0250] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 2,000 cps to about 25,000 cps at about 25°C.

[0251] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 5,000 cps to about 25,000 cps at about 25°C.

15 [0252] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 2,000 cps to about 18,000 cps at about 25°C.

[0253] In another embodiment, the pharmaceutical composition has a viscosity that ranges from about 5,000 cps to about 18,000 cps at about 25°C.

20 [0254] Viscosity is determined using a Brookfield DV-E viscometer (commercially available from Brookfield of Middleboro, MA)

[0255] In one embodiment, the pharmaceutical composition is substantially free of water. Pharmaceutical compositions that are substantially free of water are advantageous since they are not conducive to bacterial growth. Accordingly, it is typically not necessary to include a preservative in pharmaceutical compositions that
25 are substantially free of water. However, in some embodiments, the non-aqueous pharmaceutical composition contains a preservative.

[0256] In one embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Tobramycin or a pharmaceutically acceptable salt thereof, Terbinafine or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0257] In another embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Tobramycin decanoic fatty acid salt, Terbinafine decanoic fatty acid salt, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0258] In another embodiment, the pharmaceutical composition comprises from about 0.2 to about 7 wt% hydroxypropyl methyl cellulose, from about 3 to about 20 wt% glycerol, from about 65 to about 86 wt% glycerol formal, from about 0.5 to about 3 wt% of Tobramycin decanoic fatty acid salt, from about 0.5 to about 3 wt% of Terbinafine decanoic fatty acid salt, and from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0259] In another embodiment, the pharmaceutical composition comprises about 4 wt% hydroxypropyl methyl cellulose, from about 9 to about 10 wt% glycerol, from about 78 to about 85 wt% glycerol formal, about 1 wt% of Tobramycin decanoic fatty acid salt, about 1 wt% of Terbinafine decanoic fatty acid salt, and about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0260] In another embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Tobramycin or a pharmaceutically acceptable salt thereof, Terbinafine or a pharmaceutically acceptable salt thereof, Betamethasone or a pharmaceutically acceptable salt thereof, and Benzethonium chloride.

[0261] In another embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Tobramycin decanoic fatty acid salt, Terbinafine decanoic fatty acid salt, Betamethasone or a pharmaceutically acceptable ester thereof, and Benzethonium chloride.

[0262] In another embodiment, the pharmaceutical composition comprises from about 0.2 to about 7 wt% hydroxypropyl methyl cellulose, from about 3 to about 20 wt% glycerol, from about 65 to about 86 wt% glycerol formal, from about 0.5 to about 3 wt% of Tobramycin decanoic fatty acid salt, from about 0.5 to about 3 wt%
5 of Terbinafine decanoic fatty acid salt, from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof, and from about 0.005 to about 0.1 wt% of Benzethonium chloride.

[0263] In another embodiment, the pharmaceutical composition comprises about 4 wt% hydroxypropyl methyl cellulose, from about 9 to about 10 wt% glycerol, from
10 about 78 to about 85 wt% glycerol formal, about 1 wt% of Tobramycin decanoic fatty acid salt, about 1 wt% of Terbinafine decanoic fatty acid salt, about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof, and about 0.02 wt% of Benzethonium chloride.

[0264] In one embodiment, the pharmaceutical composition comprises
15 poly(acrylic acid), glycerol, poly(ethylene glycol), Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0265] In another embodiment, the pharmaceutical composition comprises a crosslinked poly(acrylic acid), glycerol, poly(ethylene glycol) having an average
20 molecular weight of about 400 g/mol, Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine oleic fatty acid salt, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0266] In another embodiment, the pharmaceutical composition comprises from about 0.1 to about 5 wt% crosslinked poly(acrylic acid), from about 5 to about 30
25 wt% glycerol, from about 60 to about 93 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol, from about 0.5 to about 3 wt% of Florfenicol or a pharmaceutically acceptable ester thereof, from about 0.5 to about 3 wt% of Terbinafine oleic fatty acid salt, and from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0267] In another embodiment, the pharmaceutical composition comprises about 0.5 wt% crosslinked poly(acrylic acid), from about 19 to about 20 wt% glycerol, from about 73 to about 79 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol, about 1 wt% of Florfenicol or a pharmaceutically acceptable ester thereof, about 1 wt% of Terbinafine oleic fatty acid salt, and about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0268] In one embodiment, the pharmaceutical composition comprises poly(acrylic acid), glycerol, poly(ethylene glycol), Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine or a pharmaceutically acceptable salt thereof, Betamethasone or a pharmaceutically acceptable ester thereof, and Benzethonium chloride.

[0269] In another embodiment, the pharmaceutical composition comprises a crosslinked poly(acrylic acid), glycerol, poly(ethylene glycol) having an average molecular weight of about 400 g/mol, Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine oleic fatty acid salt, Betamethasone or a pharmaceutically acceptable ester thereof, and Benzethonium chloride.

[0270] In another embodiment, the pharmaceutical composition comprises from about 0.1 to about 5 wt% crosslinked poly(acrylic acid), from about 5 to about 30 wt% glycerol, from about 60 to about 93 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol, from about 0.5 to about 3 wt% of Florfenicol or a pharmaceutically acceptable ester thereof, from about 0.5 to about 3 wt% of Terbinafine oleic fatty acid salt, from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof, and from about 0.005 to about 0.1 wt% of Benzethonium chloride.

[0271] In another embodiment, the pharmaceutical composition comprises about 0.5 wt% crosslinked poly(acrylic acid), from about 19 to about 20 wt% glycerol, from about 73 to about 79 wt% poly(ethylene glycol) having an average molecular weight of about 400 g/mol, about 1 wt% of Florfenicol or a pharmaceutically acceptable ester thereof, about 1 wt% of Terbinafine oleic fatty acid salt, about 0.1

wt% of Betamethasone or a pharmaceutically acceptable ester thereof, and about 0.02 wt% of Benzethonium chloride.

[0272] In one embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Gentamicin or a
5 pharmaceutically acceptable salt thereof, Clotrimazole or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0273] In another embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Gentamicin decanoic
10 fatty acid salt, Clotrimazole decanoic fatty acid salt, and Betamethasone or a pharmaceutically acceptable ester thereof.

[0274] In another embodiment, the pharmaceutical composition comprises from about 0.2 to about 7 wt% hydroxypropyl methyl cellulose, from about 3 to about 20
15 wt% glycerol, from about 65 to about 86 wt% glycerol formal, from about 0.5 to about 3 wt% of Gentamicin decanoic fatty acid salt, from about 0.5 to about 3 wt% of Clotrimazole decanoic fatty acid salt, and from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0275] In another embodiment, the pharmaceutical composition comprises about 4
20 wt% hydroxypropyl methyl cellulose, from about 9 to about 10 wt% glycerol, from about 78 to about 85 wt% glycerol formal, about 1 wt% of Gentamicin decanoic fatty acid salt, about 1 wt% of Clotrimazole decanoic fatty acid salt, and about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof.

[0276] In another embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Gentamicin or a
25 pharmaceutically acceptable salt thereof, Clotrimazole or a pharmaceutically acceptable salt thereof, Betamethasone or a pharmaceutically acceptable salt thereof, and Benzethonium chloride.

[0277] In another embodiment, the pharmaceutical composition comprises hydroxypropyl methyl cellulose, glycerol, glycerol formal, Gentamicin decanoic

fatty acid salt, Clotrimazole decanoic fatty acid salt, Betamethasone or a pharmaceutically acceptable ester thereof, and Benzethonium chloride.

[0278] In another embodiment, the pharmaceutical composition comprises from about 0.2 to about 7 wt% hydroxypropyl methyl cellulose, from about 3 to about 20 wt% glycerol, from about 65 to about 86 wt% glycerol formal, from about 0.5 to about 3 wt% of Gentamicin decanoic fatty acid salt, from about 0.5 to about 3 wt% of Clotrimazole decanoic fatty acid salt, from about 0.01 to about 0.5 wt% of Betamethasone or a pharmaceutically acceptable ester thereof, and from about 0.005 to about 0.1 wt% of Benzethonium chloride.

[0279] In another embodiment, the pharmaceutical composition comprises about 4 wt% hydroxypropyl methyl cellulose, from about 9 to about 10 wt% glycerol, from about 78 to about 85 wt% glycerol formal, about 1 wt% of Gentamicin decanoic fatty acid salt, about 1 wt% of Clotrimazole decanoic fatty acid salt, about 0.1 wt% of Betamethasone or a pharmaceutically acceptable ester thereof, and about 0.02 wt% of Benzethonium chloride.

4.7 Methods of treating or preventing a condition in an animal

[0280] In one embodiment, the method of treating or preventing a condition in an animal comprises administering to the animal in need thereof a therapeutically effective amount of a pharmaceutically active agent by otically applying a pharmaceutical composition of the invention.

[0281] In one embodiment, the method of treating or preventing a condition in an animal comprises administering to the animal in need thereof a therapeutically effective amount of a pharmaceutically active agent by ophthalmically applying a pharmaceutical composition of the invention.

[0282] In one embodiment, the method of treating or preventing a condition in an animal comprises administering to the animal in need thereof a therapeutically effective amount of a pharmaceutically active agent by topically applying a pharmaceutical composition of the invention.

[0283] The pharmaceutical compositions of the invention can also be administered orally. To administer the pharmaceutical compositions orally, the pharmaceutical composition can, for example, be encapsulated in a capsule, such as a hard gelatin capsule or a soft gelatin capsule, and the capsule orally administered to the animal.

5 Suitable capsules for use in the invention are Shionogi Qualicaps (commercially available from and Shionogi & Co., Ltd of Osaka, Japan). Oral dosage forms can be designed to release the pharmaceutically active compound in the stomach immediately or almost immediately or to provide sustained release of the pharmaceutically active compound in the stomach. The oral dosage forms can also
10 be designed to release the pharmaceutically active compound in the intestines immediately or almost immediately or to provide sustained release of the pharmaceutically active compound in the intestines. To delay the release of the pharmaceutically active compound until the dosage form reaches the intestines, the capsule is coated with an enteric coating. Typically, the enteric coating is a pH
15 sensitive polymer such as Eudragit® L-100 (commercially available from DeGussa AG of Frankfurt, Germany). The rate of release of the pharmaceutically active compound is varied by varying, for example, the amount of polymer in the pharmaceutical composition, the degree of polymer cross-linking, and the solvent in the pharmaceutical composition.

20 [0284] The pharmaceutical compositions of the invention are viscous compositions. Viscous compositions containing drugs have advantages over less viscous (thinner) liquid formulations for treating or preventing conditions in animals. For example, in topical applications, otic applications, and ophthalmic applications, especially in veterinary uses, thinner liquid formulations are easily be
25 washed or swept away from a target area of delivery than formulations that are more viscous (thicker). For treating conditions such as microbial infections, particularly in non-human animals, the advantages of thicker pharmaceutical compositions include maintaining the pharmaceutically active agent, like an antibiotic, in the target area for longer periods of time.

30 [0285] The pharmaceutical compositions of the invention are particularly useful in veterinary medicine, especially for otic applications. For example, when treating or

preventing otic microbial infections in small animals, such as cats and dogs, the pharmaceutical composition is typically administered in an amount of about 0.5 mL per ear. Larger amounts, however, can be administered for larger animals.

[0286] The pharmaceutical compositions of the invention are advantageous in veterinary medicine, especially for otic application, compared to commercially available pharmaceutical compositions. For example, when treating or preventing otic microbial infections in animals using commercially available pharmaceutical compositions the animal typically shakes its head and dislodges the composition from the target infected area (and often out of the ear entirely). This occurs readily with commercially available antibiotic compositions since they have lower viscosity. However, the pharmaceutical compositions of the invention, having a higher viscosity, are not as easily dislodged, thus rendering them more effective in delivering the pharmaceutically active agent to the target infected area and remaining present for extended periods at the infected area to provide controlled- or sustained- release of the pharmaceutically active agent.

[0287] Advantageously, the pharmaceutical compositions of the invention need to be applied less frequently than commercially available pharmaceutical compositions. Often only two doses or a single dose of the pharmaceutical compositions of the invention are effective at treating or preventing otic microbial infections in animals. In contrast, commercially available pharmaceutical compositions typically require many more doses. For example, OTOMAX® (commercially available from Schering-Plough Animal Health of Union, NJ) requires 2 doses per day for 7 days.

[0288] Further, the pharmaceutical compositions of the invention are typically more lipophilic than aqueous or semi-aqueous formulations. Without being bound by theory, it is believed that the increased lipophilicity of the pharmaceutical compositions of the invention renders them more effective than aqueous or semi-aqueous formulations, particularly for treating or preventing ear infections in an animal, because the pharmaceutical compositions of the invention are more compatible with the highly lipophilic environment of the animal's ear.

[0289] The pharmaceutical compositions of the invention also adhere well to the skin and, accordingly, are useful for topical application.

[0290] The pharmaceutical compositions of the invention can provide controlled- or sustained- release of the pharmaceutically active agent in a effective amount for up to about 15 days and even longer.

[0291] In one embodiment, the pharmaceutical compositions according to the invention provide controlled- or sustained- release of the pharmaceutically active agent in a pharmaceutically effective amount for at least about 4 to about 15 days.

[0292] In another embodiment, the pharmaceutical compositions according to the invention provide controlled- or sustained- release of the pharmaceutically active agent in a pharmaceutically effective amount for at least about 4 to about 10 days.

[0293] In another embodiment, the pharmaceutical compositions according to the invention provide controlled- or sustained- release of the pharmaceutically active agent in a pharmaceutically effective amount for at least about 1 week.

[0294] In one embodiment, the animal is a non-human animal.

[0295] In another embodiment, the animal is a human.

[0296] In another embodiment, the animal is a cat.

[0297] In another embodiment, the animal is a dog.

[0298] In another embodiment, the animal is a cow.

[0299] In another embodiment, the animal is a pig.

[0300] In another embodiment, the animal is a sheep.

[0301] In another embodiment, the animal is a horse.

[0302] In a preferred embodiment, the pharmaceutical compositions according to the invention, by providing controlled- or sustained- release of the pharmaceutically active agent, have reduced toxicity, particularly in small animals such as cats and

dogs. Accordingly, the pharmaceutical compositions according to the invention have a better therapeutic profile than conventional immediate release formulations. Methods that involve administering a pharmaceutically active agent to an animal by topically, otically, or ophthalmically applying a pharmaceutical composition of the invention permit pharmaceutically active agents to be administered to animals that could potentially (if administered in presently available dosage forms) result in toxicity and even death of the animal being treated. By advantageously providing controlled- or sustained- release of the pharmaceutically active agents, the pharmaceutical composition of the invention can be administered less frequently and therefore also be easier to administer, more convenient, and more cost effective than conventional modes of administering pharmaceutically active agents.

[0303] The amount of the pharmaceutically active agent(s) that is(are) effective in treating or preventing a condition, *e.g.*, a bacterial infection, can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, the seriousness of the condition, and the animal being treated and can be decided according to the judgment of a practitioner and/or each animal's circumstances. Suitable effective dosage amounts, however, can typically range from about 0.1 mg/kg of body weight to about 100 mg/kg of body weight, preferably from about 1 mg/kg of body weight to about 50 mg/kg of body weight, more preferably from about 2 mg/kg of body weight to about 30 mg/kg of body weight, for example from about 5 mg/kg of body weight to about 100 mg/kg of body weight. The effective dosage amounts described herein refer to total amounts of all pharmaceutically active agents administered; that is, if more than one pharmaceutically active agent is administered, the effective dosage amounts correspond to the total amount administered.

[0304] Typically, topical compositions are applied from about 1 time each day to about 1 time each week until the condition is abated.

[0305] In one embodiment, the topical compositions are applied once each day until the condition is abated.

[0306] In another embodiment, the topical compositions are applied once each week until the condition is abated.

[0307] In another embodiment, the topical applications are applied for about 4 weeks.

5 [0308] In another embodiment, the topical applications are applied for about 3 weeks.

[0309] In another embodiment, the topical applications are applied for about 2 weeks.

10 [0310] In another embodiment, the topical applications are applied for about 1 week.

[0311] In one embodiment, an effective dosage amount is administered about every 7 days until the condition is abated.

[0312] In another embodiment, an effective dosage amount is administered about every 7 days for about 4 weeks.

15 [0313] In another embodiment, an effective dosage amount is administered about every 7 days for about 2 weeks.

[0314] In another embodiment, a single effective dosage amount is administered.

[0315] In another embodiment, 2 effective dosage amount are administered about 24 hours apart.

20 [0316] In another embodiment, 2 effective dosage amount are administered about 48 hours apart.

[0317] In another embodiment, an effective dosage amount is administered about every 24 hours until the condition is abated.

25 [0318] In another embodiment, an effective dosage amount is administered about every 12 hours until the condition is abated.

[0319] In another embodiment, an effective dosage amount is administered about every 24 hours for about 4 weeks.

[0320] In another embodiment, an effective dosage amount is administered about every 12 hours for about 4 weeks.

5 [0321] In another embodiment, an effective dosage amount is administered about every 24 hours for about 2 weeks.

[0322] In another embodiment, an effective dosage amount is administered about every 12 hours for about 2 weeks.

10 [0323] In another embodiment, an effective dosage amount is administered about every 24 hours for about 1 week.

[0324] In another embodiment, an effective dosage amount is administered about every 12 hours for about 1 week.

[0325] In another embodiment, an effective dosage amount is administered about every 7 days for about 2 weeks.

15 [0326] In another embodiment, an effective dosage amount is administered daily until the condition is abated. The total dose may optionally be divided into daily doses and/or into about 2 to about 4 individual doses.

[0327] In one embodiment, the condition is a bacterial infection.

20 [0328] Representative bacterial infections that can be treated using the pharmaceutical compositions of the invention include, but are not limited to, bacterial infections caused by bacteria of the genus *Pasteurella*, *Haemophilus*, *Fusobacterium*, *Moraxella*, *Bacteroides*, *Aeromonas*, *Escherichia*, *Enterobacter*, *Klebsiella*, *Salmonella*, *Shigella*, *Serratia*, *Ureaplasma*, *Chlamydia*, *Actinobacillus*, *Streptococcus*, *Edwardsiella*, *Staphylococcus*, *Enterococcus*, *Bordetella*, *Proteus*,
25 *Mycoplasma*, or *Mannheimia*.

[0329] Representative bacterial infections that can be treated using the pharmaceutically active agents of the invention include, but are not limited to, bacterial infections caused by *Pasteurella haemolytica*, *Pasteurella multocida*, *Pasteurella haemolytica*, *Haemophilus somnus*, *Actinobacillus pleuropneumoniae*,
 5 *Actinomyces pyogenes*, *Pseudomonas aeruginosa*, *Klebsiella Pneumonia*, *Escherichia Faecalis*, *Escherichia Coli*, *Staphylococcus Aureaus*, *Streptococcus Pyogenes*, *Bacillus Subtilis*, *Streptococcus* spp., *Staphylococcus* spp., *Moraxella* spp., *Salmonella* spp., *Bacteroides* spp., *Peptococcus indolicus*, *Fusobacterium* spp., *Mycoplasma bovis*, *Mycoplasma dispar*, *Ureaplasma* spp., *Chlamydia* spp.,
 10 *Mycoplasma mycoides*, *Mycoplasma ovipneumonia*, *Haemophilus influenzae*, *Klebsiella salmonella*, *Shigella*, *Proteus Enterobacter*, *Serratia*, and *Bordetella bronchoseptica*.

[0330] Without being bound by theory, it is believed that the presence of a non-aqueous gel surrounding or encapsulating the pharmaceutically active agent(s)
 15 allows for higher loading than that attainable in aqueous gels (where the maximum loading is believed to be about 0.3 percent by weight of the aqueous pharmaceutical composition) or through the use of liposomal formulations (where the maximum loading is believed to be about 1 percent by weight of the liposome-containing composition). Indeed, a pharmaceutical composition containing uniformly dispersed
 20 pharmaceutically active agents has been formulated to contain at least as much as about 5 percent by weight of the pharmaceutical compositions of the invention.

4.8 Kits

[0331] The invention encompasses kits that can simplify the administration of a
 25 pharmaceutically active agent to an animal. A typical kit of the invention comprises a unit dosage form of a pharmaceutical composition according to the invention. In one embodiment, the unit dosage form is a container (such as a vial, a pouch, a tube, a syringe, or the like), which can advantageously be sterile, containing a pharmaceutical composition of the invention. The kit can further comprise a label or
 30 printed instructions instructing the use of the pharmaceutically active agent to treat or prevent a condition. In another embodiment, the kit comprises a unit dosage form

of a pharmaceutical composition of the invention and a dropper, syringe, or other applicator for administering the pharmaceutical composition. Typically, the components of the kit, for example, the unit dosage form and instructions, are contained within a suitable packaging material.

5

5. Examples

[0332] The following examples are set forth to assist in understanding the invention and should not be construed as specifically limiting the invention described and claimed herein. Such variations of the invention, including the substitution of all equivalents now known or later developed, which would be within the purview of those skilled in the art, and changes in formulation or minor changes in experimental design, are to be considered to fall within the scope of the invention incorporated herein.

Example 5.1: Polymer-solvent pharmaceutical composition of the invention

[0333] A mixture of about 63 grams glycerol and about 523.3 grams of stabilized glycerol formal was added to an empty flask. To the resulting mixture was added about 5 grams of Tobramycin, about 5 grams of Terbinafine, about 12.7 grams of decanoic acid, about 0.5 grams of Betamethasone acetate, and about 0.1 grams of Benzethonium chloride preservative with stirring. The resulting solution was stirred at about 40°C to provide a clear solution. About 20 grams of HPMC (hydroxypropyl methyl cellulose) was then added to the clear solution, and the resulting solution was homogenized at about 3000 rpm with an Omni International model GLH Homogenizer (commercially available from Omni International of Marietta, GA) for about 3 minutes. The homogenized solution was allowed to sit undisturbed, in the dark, at a temperature of about 20-25°C for about 12 hours. The resulting gel contained about 1 wt% Tobramycin as a decanoic acid salt, about 1 wt% Terbinafine as a decanoic acid salt, about 0.1 wt% Betamethasone acetate, and about 0.02 wt% Benzethonium chloride, and exhibited a viscosity of about 8,020 cps at 25°C.

Example 5.2: Polymer-solvent pharmaceutical composition of the invention

[0334] About 63 grams glycerol, about 5 grams of Tobramycin, about 3.75 grams of Terbinafine, about 3.2 grams of oleic acid, about 3.9 grams of decanoic acid, about 2 grams of acetic acid, about 0.5 grams of Betamethasone acetate, and about 0.1 grams of Benzethonium chloride preservative were combined in a flask with stirring. Stabilized glycerol formal was added to provide a total volume of about 500 mL. The resulting solution was then sonicated for about 10 minutes at a temperature of about 40°C to provide a clear solution. The clear solution was then cooled to a temperature of about 20-25°C. The final weight of the about 500 mL solution was about 605 grams. The solution was then transferred to a 1L beaker and equilibrated in a water bath at about 40°C. About 20 grams of HPMC (hydroxypropyl methyl cellulose) was then added to the clear solution, which was then homogenized at about 3000 rpm with an Omni International model GLH Homogenizer (commercially available from Omni International of Marietta, GA) for about 3 to about 5 minutes. The resulting homogenized solution was left undisturbed at about 40°C for about 5 minutes, sonicated at about 40°C for about 5 minutes to remove all visible bubbles from the solution, and allowed to sit undisturbed, in the dark, at a temperature of about 20-25°C for about 12 hours to provide a gel. The resulting gel contained about 1 wt% Tobramycin as a mixture of decanoic acid, oleic acid, and acetic acid salts; about 1 wt% Terbinafine as a mixture of decanoic acid, oleic acid, and acetic acid salts; about 0.1 wt% Betamethasone acetate; and about 0.02 wt% Benzethonium chloride; and exhibited a viscosity of about 4,188 cps at 25°C.

Example 5.3: Polymer-solvent pharmaceutical composition of the invention

[0335] About 126 grams glycerol, about 5 grams of Florfenicol, about 5 grams of Terbinafine, about 6.5 grams of oleic acid, about 0.5 grams of Betamethasone acetate, and about 0.1 grams of Benzethonium chloride preservative were combined in a flask. About 430 grams of polyethylene glycol 400 (PEG 400) was added to the flask and the resulting solution was stirred at about 43°C for about 45 minutes and then sonicated for about 5 minutes to provide a clear solution. The clear solution was then equilibrated in a water bath at about 40°C, and about 2.5 grams of CARBOMER™ 941 (crosslinked poly(acrylic acid) polymer, commercially

available from Noveon, Inc., of Cleveland, OH) was added to the solution. The solution was then homogenized at about 3000 rpm using a Omni International model GLH Homogenizer (commercially available from Omni International of Marietta, GA) for about 5 minutes and then sonicated for about 5 minutes to remove all visible
5 bubbles from the solution. The solution was allowed to sit undisturbed, at a temperature of about 20-25°C for about 12 hours to provide a clear gel. The resulting gel contained about 1 wt% Florfenicol, about 1 wt% Terbinafine as an oleic acid salt, about 0.1 wt% Betamethasone acetate, and about 0.02 wt% Benzethonium chloride, and exhibited a viscosity of about 2,002 cps at 25°C.

10 **Example 5.4: Polymer-solvent pharmaceutical composition of the invention**

[0336] About 50.4 grams of glycerol were added to a first flask and sufficient ethyl lactate added to provide a volume of about 140 mL. The resultant mixture of solvents was stirred and heated to about 40°C. About 2.0 grams of Tobramycin and about 3.8 g of decanoic acid were added to the mixture of solvents and the resultant
15 solution stirred until clear.

[0337] In a second flask was added about 2.0 grams of Terbinafine and about 2.88 mL of oleic acid and the resulting mixture heated to about 40°C. To the resultant mixture was added sufficient ethyl acetate to provide a volume of about 60 mL. To the resultant solution was added about 200 mg of Betamethasone acetate and about
20 40 mg of Benzethonium chloride, and the solution was stirred at about 40°C until clear.

[0338] The contents of the first flask and the contents of the second flask were then combined and stirred at a temperature of about 40°C, and about 7.0 g of HPMC was added to the resulting solution with stirring. The resulting solution was then
25 allowed to sit undisturbed at a temperature of about 20-25°C for about 12 hours to provide a gel.

[0339] The resulting gel contained about 1 wt% Tobramycin as a mixture of a decanoic acid salt and oleic acid salt, about 1 wt% Terbinafine as a mixture of a decanoic acid salt and an oleic acid salt, about 0.1 wt% Betamethasone acetate, and

about 0.02 wt% Benzethonium chloride, and exhibited a viscosity of about 7,170 cps at 25°C.

Example 5.5: Polymer-solvent pharmaceutical composition of the invention

5 [0340] About 63.0 grams of glycerol, followed by PEG 400 (about 398.2 g) and oleic acid (about 6.5 g), were added to a first flask and the resultant mixture of was stirred and heated to about 40°C. About 5.0 grams of Terbinafine, about 5.0 g of Florfenicol, about 500 mg of Betamethasone acetate, and about 100 mg of Benzethonium chloride were added to the mixture, and the resultant solution stirred for about 1 hour at a temperature of about 40°C until clear.

10 [0341] In a 50 mL centrifuge tube was added about 12 g of PEG 400 followed by about 1.25 g of CARBOMER™ 941 (crosslinked poly(acrylic acid) polymer, commercially available from Noveon, Inc., of Cleveland, OH). The resultant mixture was mixed well using a vortex mixer and then combined with the contents of the first flask with stirring at a temperature of about 40°C. The steps of adding
15 about 12 g of PEG 400 followed by about 1.25 g of CARBOMER™ 941 (crosslinked poly(acrylic acid) polymer, commercially available from Noveon, Inc., of Cleveland, OH) to a 50 mL centrifuge tube, mixing the resultant mixture well using a vortex mixer, and adding the resultant mixture to the contents of the first flask with stirring at a temperature of about 40°C was repeated 2 more times. The
20 contents of the first flask were then stirred for about 60 minutes at a temperature of about 40°C. The resulting contents of the first flask was then allowed to sit undisturbed at a temperature of about 20-25°C for about 12 hours to provide a gel.

[0342] The resulting gel contained about 1 wt% Terbinafine as an oleic acid salt, about 1 wt% Florfenicol, about 0.1 wt% Betamethasone acetate, and about 0.02 wt%
25 Benzethonium chloride, and exhibited a viscosity of about 35,480 cps at 25°C.

Example 5.6: Treatment of a fungal infection in a human using a pharmaceutical composition of the invention

[0343] The pharmaceutical composition of Example 5.5 was administered to the foot of a 24 year-old male suffering from Athlete's foot. The pharmaceutical
30 composition was administered once a week for 3 weeks. After 3 weeks, the subject

noted a disappearance in symptoms of the fungal infection, such as reduced itching, redness, and inflammation.

Example 5.7: Stability of the Pharmaceutical Compositions

[0344] A pharmaceutical composition prepared as described in Example 5.1, was incubated at a temperature of about 40°C or about 70°C for up to 7 days to monitor the degradation of Terbinafine as a function of time and temperature. Only Terbinafine was monitored, since Terbinafine is known to be the least stable component of the pharmaceutical composition of Example 8.1. The concentration of Terbinafine was determined at each time point by the following HPLC procedure:

About 200 mg of the pharmaceutical composition is weighed into a 100 mL volumetric flask and the flask is filled to volume with about a 50:50 mixture of about 25 mM phosphate buffer at about pH 2.4 and about a 50:50 mixture of methanol:acetonitrile and shaken for about 1 minute. About 2 mL of the resulting solution is then filtered through an Acrodisc 25 mm syringe filter (0.2 µm Ultipore nylon membrane), and about 10 µL of the filtered solution is injected onto a Phenomenex Luna, 5 µm, C8 100A, 250 mm x 4.6 mm, analytical HPLC column. The HPLC is operated at a flow rate of about 1 mL/min and eluted with about 50% of about 25 mM phosphate buffer at about pH 2.4 and about 50% of about a 50:50 mixture of methanol:acetonitrile for about 40 minutes. The HPLC is equipped with a UV detector. Terbinafine is detected at about 223 nm.

[0345] The results of the stability test is provided in Table 1.

Table 1. Stability of Terbinafine in the Pharmaceutical Composition of Example 5.1.

Temperature (°C)	Time (days)	% Degradation)
40	1	1.1
40	2	1.2
40	3	2.8
40	4	1.8
40	5	1.2
40	6	1.5
40	7	2.2

70	1	1.1
70	2	1.2
70	3	1.8
70	4	-0.3
70	5	1.9
70	6	3.0
70	7	-17.2

[0346] The data in Table 1 shows that the pharmaceutical composition of Example 5.1 has good stability.

5

Example 5.8: Clinical Studies

[0347] Several dogs with ear infections were administered the pharmaceutical composition of Example 5.1 or 5.5.

10 [0348] The following protocol was followed to evaluate the clinical efficacy of the pharmaceutical compositions of the invention.

[0349] Dogs with ear infections were examined by a veterinarian on day 0, and each ear was assigned a clinical score based on the following signs related to otitis externa: pain, erythema, exudate, swelling, odor and ulceration. The following scale was used:

15

Pain: 0 = none
1 = mild/moderate: painful on palpation
2 = severe: painful when raise the pinna

20

Erythema

0 = none
1 = mild/moderate: barely perceptible to obvious redness
visible with otoscope
2 = severe: beet or cherry red or erythema extends into pinna

25

Exudate

0 = none
1 = mild/moderate: small amount visible in ear canal

2 = severe: extending out of ear canal and may be crusted

Swelling

0 = none

1 = mild/moderate: some occlusion of ear canal

2 = severe: canal completely occluded

Odor

0 = none

1 = mild/moderate: malodor evident when pinna raised

2 = severe: malodor evident without raising pinna to expose

ear canal

Ulceration

0 = none

1 = mild/moderate: mild abrasions

2 = severe: abrasions that may be bleeding

[0350] The score for pain, erythema, exudate, swelling, odor and ulceration was combined to provide total clinical score ranging from 0 to 12 with 12 being the most severe otitis externa and 0 being the least severe otitis externa.

[0351] On day 0 the dog also received a physical exam, an ear swab was obtained to submit for a bacterial and yeast culture, and a second ear swab was obtained to prepare a roll smear to identify bacteria and/or yeast. The dogs ear was also cleaned with a cleansing solution free of antimicrobial and anti-inflammatory activity, and excess solution was removed from the ear. About 0.5 mL of the pharmaceutical composition of Example 5.1 or 5.5 was then administered to each infected ear and the ears massaged to distribute the pharmaceutical composition.

[0352] On day 7 (\pm 2 days) a clinical score was again assigned to each ear using the same scale as used on day 0. On day 7 (\pm 2 days) 0.5 mL of the same pharmaceutical composition as was administered on day 0 was again administered to each infected ear and the ears massaged to distribute the pharmaceutical composition.

[0353] On day 14 (\pm 2 days) a clinical score was again assigned to each ear using the same scale as used on day 0.

[0354] Various breeds of dogs were used in the study of both sexes, various body weights, and physiological states. All dogs were at least about 8 weeks old and in

general good health. For inclusion in the study the dogs had a minimum total clinical score on day 0 of about 6, received no treatment with systemic or otic antimicrobials or anti-inflammatories within the last month, had intact tympanic membranes, exhibited visualization of bacteria or yeast on the roll smear, and possessed no concurrent *Otodectes cynotis* infections.

[0355] The results of the study are provided below in Table II. Dogs in Group A were treated with the pharmaceutical composition of example 5.1 and dogs in Group B were treated with the pharmaceutical composition of example 5.5.

Table II

Animal No.	Score					
	Day 0		Day 7		Day 14	
	Left Ear	Right Ear	Left Ear	Right Ear	Left Ear	Right Ear
Group A¹						
3	6	2	3	2	2	1
6	11	0	4	0	4	0
9	6	6	3	3	2	2
12	12	11	12	10	12	12
Group B²						
2	8	4	3	3	2	1
5	12	12	7	8	2	3
8	6	8	5	5	5	5
11	8	9	1	2	5	5
14	12	0	9	0	12	0

¹ Dogs in Group A were treated with the pharmaceutical composition of example 8.1.

² Dogs in Group B were treated with the pharmaceutical composition of example 8.5.

[0356] The data in Tables II clearly shows that the pharmaceutical composition of the invention are effective at treating otic microbial infections in dogs.

Example 5.9

A program was initiated to develop a pharmaceutical composition containing a combination of an antibacterial agent, an antifungal agent, and a steroid in the form of a gel.

During the development process it was attempted to make a non-aqueous gel. It was observed, however, that combining polymers (in particular, cellulose polymers) with most organic solvents did not provide a gel. Specifically, the formation of a gel was only observed when hydroxypropylmethyl cellulose ("HMPC") was combined with glycerol formal, ethyl lactate, or a

mixture thereof. The combination of HMPC and glycerol formal, ethyl lactate, or a mixture thereof was critical to formation.

Provided below in Table III is a tabulation describing illustrative solvents and cellulose polymers (other than HMPC) that were combined and whether or not a gel formed.

5 **Table III**

Gel Formation of Various Cellulose Polymers in Various Solvents						
Polymer	Solvent					
	Ethyl lactate	Polyethylene glycol 400	Propylene glycol	Propylene carbonate	Stabilized glycerol formal	Tetraglycol
Methyl cellulose	No*	No*	No*	No*	No*	No*
Ethyl cellulose	No*	No*	No*	No*	No*	No*
2-Hydroxyethyl cellulose	No*	No*	No*	No*	No*	No*
Hydroxypropyl cellulose	No*	No*	No*	No*	No*	No*
Cellulose acetate	No*	No*	No*	No*	No*	No*
Cellulose acetate hydrogenphthalate	No*	No*	No*	No*	No*	No*
Hydroxypropylmethyl cellulose phthalate	No*	No*	No*	No*	No*	No*

No* means that a gel did not form.

10 In each of the above-identified compositions, a concentration of the cellulose polymer in the solvent of 1%, 3%, and 6% by weight was used. As can be clearly seen from the illustrative experiments described in Table III, none of the cellulose polymers formed a gel with any of the solvents, including glycerol formal and ethyl lactate.

Provided below in Table IV is a tabulation describing illustrative solvents that were combined with the polymer HMPC and whether or not a gel formed.

Table IV

Gel Formation of Hydroxypropylmethyl Cellulose (HMPC) in Various Solvents	
Solvent	Gel Formation
Ethyl lactate	Gel formation observed
Polyethylene glycol 400	No*
Propylene glycol	No*
Propylene carbonate	No*
Stabilized glycerol formal	Gel formation observed
Tetraglycol	No*
1:1 Propylene carbonate and stabilized glycerol formal	Gel formation observed
Dimethylsulfoxide	No*
Methanol	No*
Ethanol	No*
N-methyl pyrrolidine	No*

No* means that a gel did not form.

In each of the above-identified compositions, the concentration of the HMPC in the solvent was 6% by weight. As can be clearly seen from the illustrative experiments described in Table IV, HMPC only formed a gel in solvent systems that included the solvents ethyl lactate or glycerol formal.

The above described results clearly illustrate that the combination of HMPC and ethyl lactate or glycerol formal is unique in that it forms a gel. In contrast, (i) the combination of other cellulose polymers and solvents (including glycerol formal and ethyl lactate) or (ii) the combination of HMPC with solvents other than glycerol formal or ethyl lactate do not form gels.

Furthermore, in addition to forming a gel, a composition containing HMPC in combination with glycerol formal, ethyl lactate, or a mixture thereof is capable of dissolving each of an antibacterial agent, an antifungal agent, and a steroid. When formulating a pharmaceutical composition, containing multiple active ingredients, including gel compositions, it is advantageous if each of the active ingredients are soluble in the composition. When each of the active ingredients are soluble in the composition, separation of one or more active ingredients is avoided and uneven distribution of the active ingredients in the composition is advantageously avoided. Thus, the compositions recited herein, which are a solution in the form of a gel, are advantageous compared to a suspension.

During the development process it was also attempted to form a non-aqueous gel by combining the polymer (poly)acrylic acid with a variety of organic solvents. Again, it was observed that the combination of (poly)acrylic acid with most solvents did not provide a gel. Specifically, a gel was only formed when poly(acrylic) acid was combined with the solvent polyethylene glycol. Thus, the combination of poly(acrylic) acid with polyethylene glycol is critical to the formation of a gel.

Provided below in Table V is a tabulation describing illustrative solvents that were combined with (poly) acrylic acid and whether or not a gel formed. The (poly) acrylic acids used in this study were commercially available Carbomer 940 and Carbomer 941 (commercially available from B. F. Goodrich of Cincinnati, Ohio), which are cross-linked (poly) acrylic acids.

Table V

Gel Formation of (Poly) acrylic Acid¹ in Various Solvents	
Solvent	Gel Formation
Ethyl lactate	No*
Polyethylene glycol 400	Gel formation observed
Propylene glycol	No*
Propylene carbonate	No*
Stabilized glycerol formal	No*
Tetraglycol	No*
1:1 Propylene carbonate and stabilized glycerol formal	No*
Dimethylsulfoxide	No*
Methanol	No*
Ethanol	No*
N-methyl pyrrolidine	No*

No* means that a gel did not form.

¹ Carbomer 940 and Carbomer 941

In each of the above-identified compositions, the concentration of (poly) acrylic acid in the solvent was 6% by weight. As can be clearly seen from the illustrative experiments described in Table V, (poly) acrylic acid only formed a gel with the solvent polyethylene glycol. Although the experiments described in Table V used a (poly) acrylic acid concentration of 6% by weight, it was also demonstrated that a gel will form when the (poly) acrylic acid concentration is as low as 0.1%.

The above described results clearly illustrate that the combination of (poly) acrylic acid with the solvent polyethylene glycol, unlike other solvents, is unique in that it forms a gel.

During the development process it was observed that combining hydroxypropyl methylcellulose ("HMPC") with either ethyl lactate or glycerol formal as a solvent was unique in that it formed a gel. In contrast, (i) the combination of other cellulose polymers with a solvent (including glycerol formal and ethyl lactate) or (ii) the combination of HMPC with a solvent other than glycerol formal or ethyl lactate did not form a gel.

Although both glycerol formal and ethyl lactate, when combined with HPMC, provided a gel, it was also observed that using glycerol formal as the solvent provided a gel with unexpected and advantageous properties. In particular, a gel made with glycerol formal showed much less discoloration over time and was more resistant to phase separation compared to a gel made using ethyl lactate.

Specifically, two compositions were prepared. The compositions were identical except that one composition contained glycerol formal as the solvent and the other composition contained ethyl lactate as the solvent. The compositions included the following components in the following amounts:

Component	Amount
Terbinafine	5 g
Oleic acid	9.36 g
Tobramycin	5 g
Benzethonium chloride	500 mg
Betamethasone acetate	500 mg
HPMC	20 G
Solvent (either glycerol formal or ethyl lactate)	q.s. 500 mL

The compositions were made by filling a 500 mL volumetric flask about 3/4 full with the solvent. Each component was then added to the flask and the resulting mixture homogenized using ultrasound for 5 minutes. The resulting solution was then warmed to 40°C and filled to volume with additional solvent at 40°C.

Each composition was then subjected to stability testing by maintaining a vial containing the composition at 40°C or at room temperature (about 25°C). The vials were visually examined on a regular basis.

The following results were observed:

Ethyl lactate composition at 40°C – after 3-4 days the composition turned yellow. The discoloration worsened over time to eventually provide a dark yellow-brown composition after about 3 months. After about 3 or 4 months the composition also exhibited phase separation, *i.e.*, the formation of two insoluble phases.

Ethyl lactate composition at room temperature – after 3-4 weeks the composition turned yellow.

Glycerol formal composition at 40°C – after about 4 months the composition showed slight discoloration (yellowing). No phase separation was observed (even after 1 year).

5 **Glycerol formal composition at room temperature** – showed no evidence of discoloration (yellowing) or phase separation for up to 1 year.

The results of the above-described stability tests shows that the composition containing glycerol formal exhibited superior stability compared to the composition containing ethyl lactate. Specifically, at 40°C, the ethyl lactate containing composition began to yellow after only 3 or 4 days
10 and, after about 3 months, became a dark yellow-brown color. The ethyl lactate composition also showed phase separation after 3 or 4 months. In contrast, the glycerol formal solution, when stored at 40°C only showed slight yellowing after about 4 months and did not undergo phase separation even after 1 year.

Similarly, the ethyl lactate containing composition, when stored at room temperature, began
15 to yellow after 3 or 4 weeks. In contrast, the glycerol formal containing solution, when stored at room temperature, showed no evidence of yellowing (or phase separation) for up to 1 year.

These results demonstrate that the compositions containing glycerol formal are much more stable than the compositions containing ethyl lactate. This stability was unexpected could not have been predicted. Stability is an important property for a pharmaceutical composition.

20 **[0357]** The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

25 **[0358]** A number of references have been cited, the entire disclosure of which are incorporated herein by reference.

The claims defining the invention are as follows:

1. A pharmaceutical composition comprising:
a solvent comprising glycerol formal;
hydroxypropyl methylcellulose; and
5 an antibacterial agent, an antifungal agent, and a steroid,
wherein the antibacterial agent, antifungal agent, and steroid are dissolved in the solvent and
the pharmaceutical composition is in the form of a gel.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition
is substantially free of water.
- 10 3. The pharmaceutical composition of claim 1 or 2, wherein the solvent further comprises
a second organic solvent selected from the group consisting of glycerol, propylene glycol,
poly(ethylene glycol), and mixtures thereof.
4. The pharmaceutical composition of claim 3, wherein the second organic solvent
comprises glycerol.
- 15 5. The pharmaceutical composition of claim 3, wherein the second organic solvent
comprises propylene glycol.
6. The pharmaceutical composition of claim 3, wherein the second organic solvent
comprises poly(ethylene glycol).
- 20 7. The pharmaceutical composition of any one of claims 1 to 6, wherein the antibacterial
agent is Tobramycin or a pharmaceutically acceptable salt thereof, the antifungal agent is
Terbinafine or a pharmaceutically acceptable salt thereof, and the steroid is Betamethasone or a
pharmaceutically acceptable ester thereof.
8. The pharmaceutical composition of claim 7, wherein the Tobramycin or a
pharmaceutically acceptable salt thereof is present in an amount ranging from about 0.5 to 3 wt%,
25 the Terbinafine or a pharmaceutically acceptable salt thereof is present in an amount ranging from
about 0.5 to 3 wt%, and the Betamethasone or a pharmaceutically acceptable ester thereof is
present in an amount ranging from about 0.01 to 0.5 wt%.
9. The pharmaceutical composition of any one of claims 1 to 6, wherein the
pharmaceutically active agent comprises Florfenicol or a pharmaceutically acceptable ester thereof,
30 the antifungal agent is Terbinafine or a pharmaceutically acceptable salt thereof, and the steroid is
Betamethasone or a pharmaceutically acceptable ester thereof.
10. The pharmaceutical composition of claim 9, wherein the Florfenicol or a
pharmaceutically acceptable ester thereof is present in an amount ranging from about 0.5 to 3 wt%
the Terbinafine or a pharmaceutically acceptable salt thereof is present in an amount ranging from

about 0.5 to 3 wt%, and the Betamethasone or a pharmaceutically acceptable ester thereof is present in an amount ranging from about 0.01 to 0.5 wt%.

11. The pharmaceutical composition of any one of claims 1 to 6, wherein the antibacterial agent is Gentamicin or a pharmaceutically acceptable salt thereof, the antifungal agent is
5 Clotrimazole or a pharmaceutically acceptable salt thereof, and the steroid is Betamethasone or a pharmaceutically acceptable ester thereof.

12. The pharmaceutical composition of claim 11, wherein the Gentamicin or a pharmaceutically acceptable salt thereof is present in an amount ranging from about 0.5 to 3 wt%, the Clotrimazole or a pharmaceutically acceptable salt thereof is present in an amount ranging from
10 about 0.5 to 3 wt%, and the Betamethasone or a pharmaceutically acceptable ester thereof is present in an amount ranging from about 0.01 to 0.5 wt%.

13. The pharmaceutical composition of any one of claims 1 to 6, wherein the amount of hydroxypropyl methylcellulose ranges from about 1 to about 4 weight percent of the composition.

14. The pharmaceutical composition of claim 13, wherein the amount of hydroxypropyl
15 methylcellulose ranges from about 3 to about 4 weight percent of the composition.

15. A pharmaceutical composition comprising:

a solvent comprising a first organic solvent selected from the group consisting of glycerol formal, ethyl lactate, and a mixture thereof;

hydroxypropyl methylcellulose in an amount ranging from about 1 to about 4 weight percent
20 of the composition; and

an antibacterial agent, an antifungal agent, and a steroid,

wherein the antibacterial agent, antifungal agent, and steroid are dissolved in the solvent; and the pharmaceutical composition is in the form of a gel.

16. The pharmaceutical composition of claim 15, wherein the amount of hydroxypropyl
25 methylcellulose ranges from about 3 to about 4 weight percent of the composition.

17. A method of treating or preventing a condition in an animal comprising topically, optically, or ophthalmically administering a therapeutically effective amount of the pharmaceutical composition of any one of claims 1 to 16.

18. The method of claim 17, wherein the animal is a non-human animal.

30 19. Use of a pharmaceutical composition according to any one of claims 1 to 16 for the manufacture of a medicament for treating or preventing a condition in an animal.

20. A pharmaceutical composition comprising:

poly(ethylene glycol);

a cross-linked poly(acrylic acid) polymer; and

35 a pharmaceutically active agent,

wherein the poly(acrylic acid) polymer is present in an amount ranging from about 0.2 to about 0.6 wt% of the pharmaceutical composition, the pharmaceutically active agent is dissolved in the poly(ethylene glycol), and the pharmaceutical composition is in the form of a gel.

21. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition
5 is substantially free of water.

22. The pharmaceutical composition of claim 20 or 21, wherein the pharmaceutical composition further comprises an organic solvent selected from the group consisting of glycerol, propylene glycol, and a mixture thereof.

23. The pharmaceutical composition of claim 22, wherein the organic solvent comprises
10 glycerol.

24. The pharmaceutical composition of claim 22, wherein the organic solvent comprises propylene glycol.

25. The pharmaceutical composition of claim 20 or 21, wherein the pharmaceutically active agent comprises an antibacterial agent, an antifungal agent, an antiparasitic agent, an anti-
15 yeast agent, an antiviral agent, an antiinflammatory agent, or a combination thereof.

26. The pharmaceutical composition of claim 25, wherein the pharmaceutically active agent comprises a combination of an antibacterial agent, an antifungal agent, and a steroid.

27. The pharmaceutical composition of claim 26, wherein the pharmaceutically active agent comprises Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine or a
20 pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

28. The pharmaceutical composition of claim 20, wherein the poly(ethylene glycol) has a number of average molecular weight below about 500 g/mol.

29. The pharmaceutical composition of claim 28, wherein the poly(ethylene glycol) has a
25 number average molecular weight of about 400 g/mol.

30. The pharmaceutical composition of claim 20 or 21, wherein the pharmaceutically active agent comprises Tobramycin or a pharmaceutically acceptable salt thereof, Terbinafine or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

31. The pharmaceutical composition of claim 30, wherein the Tobramycin or a
30 pharmaceutically acceptable salt thereof is present in an amount ranging from about 0.5 to 3 wt%, the Terbinafine or a pharmaceutically acceptable salt thereof is present in an amount ranging from about 0.5 to 3 wt%, and the Betamethasone or a pharmaceutically acceptable ester thereof is present in an amount ranging from about 0.01 to 0.5 wt%.

32. The pharmaceutical composition of claim 20 or 21, wherein the pharmaceutically active agent comprises Florfenicol or a pharmaceutically acceptable ester thereof, Terbinafine or a pharmaceutically acceptable salt thereof, and Betamethasone or a pharmaceutically acceptable ester thereof.

5 33. The pharmaceutical composition of claim 32, wherein the Florfenicol or a pharmaceutically acceptable ester thereof is present in an amount ranging from about 0.5 to 3 wt%, the Terbinafine or a pharmaceutically acceptable salt thereof is present in an amount ranging from about 0.5 to 3 wt%, and the Betamethasone or a pharmaceutically acceptable ester thereof is present in an amount ranging from about 0.01 to 0.5 wt%.

10 34. A pharmaceutical composition according to claim 1, 15 or 20, substantially as hereinbefore described with reference to any one of the examples 5.1 to 5.8.

35. A method for treating or preventing a condition in an animal comprising topically, optically, or ophthalmically administering a therapeutically effective amount of the pharmaceutical composition of any one of claims 20 to 34.

15 36. Use of a pharmaceutical composition according to any one of claims 20 to 34 for the manufacture of a medicament for treating or preventing a condition in an animal.

Dated 19 August, 2009
IDEXX Laboratories, Inc.

20

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON